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Non-insulin dependent diabetes m ellitus (NIDDM) is often associated with
hyperinsulinem ia and insulin resistance. Since there is little inform ation about
cardiovascular abnorm alities in NIDDM, this study was conducted to evaluate
the potential role of insulin resistance in two new anim al m odels of insulin
resistance, the young Zucker Diabetic Fatty (ZDF) and the Hybrid Zucker
D iabetic Fatty/S pontaneously H ypertensive Heart Model (ZD F/SHH F). To
evaluate the potential role of insulin resistance in cardiovascular abnorm alities,
the thiazolidinedione, pioglitazone (10 m g/kg/day p.o.), was used. This drug
significantly decreased plasma insulin, glucose, triglycerides and cholesterol in
young and hybrid diabetic rats.
P ioglitazone im proved the insulin resistance in the tw o NIDDM m odels.
Concurrently, there was impaired cardiac perform ance in young ZDF diabetic
rats relative to non-diabetic rats; however, there w as no im paired cardiac
perform ance in untreated diabetic rats relative to untreated non-diabetic rats as
seen in IDDM models. Pioglitazone also significantly increased body weights
and heart weights, a potentially detrimental occurrence in the NIDDM rats. The
increased heart weights seen in the pioglitazone treated diabetic rats may be
responsible for the im paired cardiac perform ance at the low er end of the
preload scale. Pioglitazone was able to decrease blood pressure in young
hybrid diabetic rats relative to non-diabetic rats even though this diabetic rat
m odel did not show ele va ted d ia b e tic blood p re ssure s.
C o rre ctin g
hyperinsulinem ia with pioglitazone may be responsible for this drug's effects
observed in the young ZDF and young hybrid ZDF/SHHF rats.
Vanadyl sulfate (0.75 m g/m l) resulted in decreased plasm a glucose and
triglycerides in young hybrid ZDF/SHHF diabetic rats without lowering plasma
insulin or modifying cardiovascular parameters. Vanadyl sulfate also lowered
plasm a glucose w ithout affecting plasma triglycerides and cholesterol in the
IDDM model (older ZDF).
Hydralazine (5 mg/kg b i d.) did not significantly affect hyperinsulinémie young
hybrid ZDF/SHHF rats except to decrease body weights increase heart weight
to body weight ratios, and decreased total cholesterol and HDL cholesterol
ratios. Hydralazine improved the rate of relaxation in hybrid ZDF/SHHF diabetic
rats.
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1 .0

IN T R O D U C T IO N

D iabetes

m ellitus,

hype rten sion ,

h yp e rllp id e m ia ,

and

h y p e rin s u lin e m ia

separately are believed to have deleterious effects on the heart.

Together,

diabetes, hypertension and h ype rlip id em ia have been show n to

have

cumulative deleterious effects in insulin-dependent diabetes m ellitus (IDDM) as
measured in the working heart model. This effect was also seen in conscious
deoxycorticosterone treated hypertensive diabetic rats (Schenk and McNeill,
1991). In non-insulin dependent diabetic (NIDDM) patients, many or all of these
phenom ena may be present and it is speculated that hyperinsulinem ia or
insulin resistance may be associated with one or more of these clinical aspects.
The overall purpose of this study was to exam ine the potential role of insulin
resistance (a key factor of NIDDM) in the development of hypertension or other
cardiovascular complications of diabetes.

Several anim al m odels of NIDDM involving insulin resistance have recently
been developed. These animals have in common the fact that they are obese
and have elevated lipids. The purpose of this study was to evaluate whether or
not drugs capable of reducing insulin resistance have the potential to reduce
cardiovascular com plications of diabetes. Three drugs (pioglitazone, vanadyl
and hydralazine) were evaluated in two animal models of NIDDM. The Zucker
diabetic fatty (ZDF) rat was selected as the first NIDDM-insulin resistant model.
In the early stages of these animals' lives, they are hyperinsuliném ie, insulin
resistant, hypertriglyceridem ic and hyperglycem ic, closely resem bling human
NID D M .

At a la te r stage in these rats' developm ent, th e y becom e

hypoinsulinem ic and more accurately resemble IDDM. These anim als remain
hyperglycem ic and hypertriglyceridem ic whether in the hyperinsulinémie phase
1
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or in the hypoinsulinemic phase. The second animal model used was a hybrid
rat m odel.

These ZD F-SH H F hybrid rats are a cross betw een the non

hypertensive Z ucke r diabetic fa tty (Z D F /D rt-fa) rat and the hypertensive
S H H F /M c c -c p

rat.

The

hybrid

rats

are

o bese,

hypertriglyceridem ic and a good rat model of NIDDM.

in s u lin -re s is ta n t,

Using their lean litter

mates as controls, the three drugs were used to evaluate their ability to improve
the diabetic and cardiovascular state.

I.1

Diabetes Mellitus

Diabetes is one of the world's most common diseases. There are several forms
of diabetes mellitus, including: type I, which is insulin-dependent (IDDM); type
II, w hich is n o n -in sulin-d ep en d en t (N ID D M ); and g esta tio n a l dia b ete s.
G e sta tion al diabetes is observed as im paired glucose to le ra n ce during
pregnancy (Brisco, 1993).

Characteristically, IDDM patients are usually not overweight, are variably aged,
have a rapid onset of the disease and require insulin therapy to stay alive.
C haracteristics shared am ong IDDM and NIDDM include hyperglycem ia,
polyuria, polydipsia and polyphagia. Most diabetics, if not properly controlled,
also exhibit hyperlipidemia. Patients with IDDM release inadequate pancreatic
insulin.

Insulin is produced and secreted by |3 (b e ta ) cells In the Islets of

Langerhans.

it is believed that IDDM occurs as a result of an autoim m une

attack on these islet cells resulting in the destruction of p cells. In this scenario,
autoreactive T lym phocytes initiate and oversee p cell sp ecific im m une
destruction (Eisenberth, 1986).
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The key to treating this type o f diabetes m ellitus is insulin therapy.

Insulin

comes in many formulations and preparations. Patients self-m onitor their blood
glucose and adm inister their insulin subcutaneously on a daily basis.

IDDM

accounts for approximately 5 to 10 percent of all diabetic patients in the United
States (ADA, 1991). Recently, a strong association between IDDM and certain
genetic markers (HLA DR3 and DR4) has been found; however, to date, most
individuals with these genetic markers do not develop diabetes.

This makes

predicting those who might become diabetic difficult. Some studies are being
conducted to look at treating potential diabetics, based on presence of these
genetic m arkers, or insulin antibodies w ith im m unosuppressants such as
cyclosporine and azathioprine to prevent or delay the onset of the disease.

NIDDM, on the other hand, is characterized by obesity (usually), hyperglycem ia
and insulin resistance (decreased tissue sensitivity or responsiveness to
insulin).

This form of diabetes m ellitus accounts for 90 to 95 percent of the

diabetics in the United States, approximately 12 million cases.

Patients with

NIDDM have a functioning pancreas and produce some insulin, but it is either
insufficient in quantity or ineffective at the tissue level. This form of the disease
can be asymptomatic for many years, has a slow progression, and is usually
inherited.

The 1991 Diabetes Vital Statistics handbook lists several major risk factors for
NIDDM:

a fam ily history of diabetes; obesity (body weight, due to fat, above

20% ideal); race (Native American, Hispanic or African Am erican); age older
than 40; previous identification of impaired glucose tolerance; hypertension or
significant hyperlipidem ia; and a history of gestational diabetes m ellitus or
delivery of a baby over 9 pounds.

O f these risk factors, obesity is the m ost
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Important. A 3-fold higher incidence of NIDDM occurs in patients 40 % above
desirable weight com pared to patients of normal body w eight (ADA, 1991).
There are many drug therapies for NIDDM. For details see section 1.5.

1.2

C om plications

There are m any com plications of diabetes mellitus, both acute and chronic.
C h ro n ic

c o m p lic a tio n s

n e p h ro p a th y

and

in clu d e

n e u ro p a th y.

c a rd io v a s c u la r
A cu te

d is e a s e ,

c o m p lic a tio n s

re tin o p a th y ,

in clu d e

d ia b e tic

ketoacidosis, hyperglycemic coma, and infections. Hypoglycemic episodes due
to overdoses of insulin or oral hypoglycemics are another complication.

Cardiovascular disease (CVD) is a term used to describe a group of diseases
that affect the heart and blood vessels. Diseases in this group include strokes,
ischem ic heart diseases such as angina and co ro na ry a rte ry disease
(a th e ro scle ro sis),

p eriph era l va s c u la r disease, v e n tric u la r h ype rtro ph y,

cardiomyopathy and heart failure. CVD is trem endously more likely in diabetic
patients than the general population.

In the United States, diabetics are 2-4

tim es more prone to die from heart disease than the non-diabetic population.
Evidence of coronary heart disease is present in 7.5 to 16.6 percent of diabetics
older than 45 years of age (ADA, 1991).
c a rd io v a s c u la r

d is e a s e

a cco u n ts

W ithin the diabetic population,

fo r tw o -th ird s

of th e

to ta l

d e a th s.

Cardiovascular disease is more common in NIDDM than IDDM, mostly because
of the age of the population. As IDDM patients age, the risk increases, but the
primary cause of death in IDDM is kidney failure. IDDM patients also represent
a large portion of the kidney transplant patients today.

R isk fa cto rs for

ca rd io va scu la r disease include hypertension, high b lo o d-cholesterol (low
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density lipoprotein, LDL, and very low density lipoprotein, VLDL) with low high
density lipoprotein (HDL) levels and cigarette smoking. Diabetes is itself a risk
factor for atherosclerotic cardiovascular disease, increasing the risk two- to
threefold (ADA, 1991).

Hypertension is reported in 50% of the adult diabetic

population compared to 25% of non-diabetics of the same age.

Lipoproteins are a group of molecules that transport cholesterol throughout the
blood stream. There are four main types of lipoproteins.

Chylomicrons are the

largest of the lipoproteins and are rich in triglycerides and transport dietary fat
and cholesterol from the intestine to the liver. Manufactured in the liver, VLDLs
are also rich in triglyceride and cholesterol, but transport the endogenous forms
of these lipids.

On capillary surfaces, VLDLs and chylom icrons interact with

lipoprotein lipase causing th e ir triglycerides to be hydrolyzed, producing
remnants called intermediate density lipoproteins (IDL) which are believed to
be atherogenic. When VLDLs are metabolized, they form another lipoprotein,
the LDL.

This lipoprotein is high in cholesterol and is referred to as bad

cholesterol and has a high association with coronary heart disease (Howard
and Howard, 1994). LDL transport cholesterol from the liver to the peripheral
tissues.

HDL, good cholesterol, acquires free cholesterol from peripheral

tissues and is este rifled by the enzym e tecithinicholesterol acyltransferase
(LCAT) to cholesteryl ester which may be transferred to LDL, IDL or VLDL by the
cholesteryl ester transfer protein (CEPT). Chylomicrons can transform into HDL
with the transfer of apotipoproteins.

One of the consequences of elevated

lipoproteins is atherosclerosis. In excess, LDLs begin to deposit in artery walls
accum ulate and eventually reduce and possibly totally occlude, blood flow.
This is atherogenesis.

LDL attaches to damaged endothelium and activated

m acrophages and begins to transform m acrophages into foam cells w ith
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cholesterol accum ulation.

After a period of time, these foam cells becom e

calcified and form a plaque.

Diabetics, who have excess plasma glucose, also

run the risk of glycosylating and oxidizing their LDLs. This form of LDL Is more
likely to be found In atherosclerotic lesions.

Oxidized LDL may also recruit

smooth muscle cells from the media to the Intima and Injure proliferating cells,
leading to accumulation of dead cells (Autio et al., 1990). Hypertriglyceridem ia
has also been shown to Induce lipid peroxidation and u ltim a te ly aid in
destruction of cells in areas of atherosclerotic lesions (HIramatsu et al., 1988).

Secondary hyperlipidem ia, not attributable to genetics, is often a result of
m etabolic disorders such as diabetes or hypothyroidism , although there are
many other causes of this condition such as alcoholism.

Hyperlipidem ia is a

condition where VLDL and LDL levels are elevated (greater than 160 mg/dl)
and HDL levels are reduced below 35 mg/dl.

Generally, untreated NIDDM

patients have normal to slightly reduced lipoprotein lipase (LPL) levels, which
some have shown to Increase with Insulin treatm ent (Tasklnen, 1987). NIDDM
patients typically have fasting hypertriglyceridemia and low HDL. The difficulty
in treating these patients is that they are usually obese and insulin resistant. It
has even been noted that with tight control of NIDDM, elevated lipids sometimes
do

not decrease.

Thus,

any tre a tm e n t s tra te g y w hich

can

co n tro l

hyperglycem ia, reduce the elevated triglycerides and LDL cholesterol, and
increase HDL cholesterol and LPL levels would be a benefit to the NIDDM
patient.

Myocardial infarction and congestive heart failure occur at a much higher rate In
diabetic populations (Jaffe, 1989).

Reduced diastolic filling rate along with

prolonged Isovolumic relaxation has been observed In diabetes (Pozzoll et al..
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1984). There are many theories explaining cardiovascular abnorm alities in the
diabetic population, including; deterioration of the m icrocirculation (Friedmann,
1989), abnorm alities in the conduction system (G arber and Neely, 1983),
abnorm alities in the m yocardium such as depressed m yocardial m etabolism
(Fevury et al., 1979), impaired tissue antioxidant status (W ohaieb and Godin,
1987), and decreased sarcolemmal enzyme activity (Pierce et al., 1983). The
exact mechanism causing or initiating diabetic cardiom yopathy is unknown;
however, intracellular calcium is believed to be crucial (Pierce, 1988; W eir,
1990, G anguly et al, 1983).

It is known that the calcium pum p of the

sarcoplasm ic reticulum, which controls calcium removal in norm al tissue, is
defective in diabetic tissue, as evidenced by decreased A T P -dependent
calcium transport and calcium stimulated ATPase activity (Ganguly et al., 1983).
C alcium regulation is im paired by o the r m echanism s as w ell, including:
decreased Na+-K+ (Pierce et al, 1990), Na+-H+ (Pierce et al, 1990), and Na+C a++ exchange processes (Makino et al., 1987), and inhibition of Ca ATPase
(Heyliger et al., 1987).

Cardiac perform ance abnorm alities have been shown in m any drug induced
and genetic animal m odels of type I diabetes.

There is very little evidence

suggesting cardiovascular problems with type II models of diabetes. A standard
method of determining cardiac performance is the working heart model.

This

procedure allows one to test the ability of the heart to respond to changes in
preload. Transducers measure maximum and minimum pressures in the heart
and heart rate. With a com puter program, left ventricular developed pressure
(LVDP), rate of contraction (+dP/dT), and rate of relaxation (-dP/dT) can be
measured directly in a heart that is perfused through the pulm onary vein and
out the aorta.
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Much recent evidence suggests that tight control of blood glucose and the
elim ination of as many risk factors as possible can delay, if not prevent, the
development of these diabetic complications. Appropriate lifestyle changes are
often sufficient to eliminate the signs and symptoms of NIDDM. In fact, NIDDM
patients are first treated with education and lifestyle changes including weight
loss and exercise. Only as a last resort are patients with NIDDM treated with
drug therapy.

1.3

Insulin

Am ong the im portant historical discoveries w ith insulin are the clin ica l
description of the disease in 20 A.D., the discovery of pancreatic islets by
Langerhans in 1869, the discovery of insulin in 1921 by Banting and Best, the
isolation and crystalization of insulin by Abel in 1927

and the synthesis of

recombinant human insulin in E. coli in 1979.

Insulin is a peptide hormone m anufactured and released from the pancreas.
Insulin mRNA is transcribed in the nucleus of the p islet cell.

A fte r being

modified, the mRNA leaves the nucleus and begins the translation process on
the rough endoplasm ic reticulum .

Here, a single chain of pre-pro-insulin is

made. This is also where the pre (24 amino acids) segment is cleaved. The pro
insulin is released in m icrovesicles which are taken up into G olgi w here
packaging into granules occurs.

In the granules three disulfide bonds form

between cys residues and the C-peptide segment (86 amino acids) is cleaved
from the pro insulin leaving equal amounts of C-peptide and insulin which are
secreted into the portal blood. Insulin exists as an A chain (20 amino acids) and
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a B chain (30 am ino acids) linked by tw o disulfide bonds w ith an intra-A
disulfide bond. It is released in response to as little as a 10 mg/dl increase in
plasma glucose levels as well as by amino acids, free fatty acids, glucagon, and
other less potent secretagogues and sym pathetic nervous stim ulation (3
adrenergic, epinephrine).

Insulin is released from the 3 cells into the blood where it binds to m em brane
bound receptors at target tissues and facilitates glucose uptake into the tissues
where it can be used. If glucose cannot be used, the body relies on free fatty
acids and amino acids as precursors. This can lead to muscle wasting, weight
loss and ketoacidosis.

Insulin's actions are anabolic and anti-ketogenic and

fa vor the storage of fat, protein and carbohydrate.

Insulin d ecreases

glycogenolysis, lipolysis, proteolysis and gluconeogenesis. Counter-regulatory
horm ones to insulin include glucagon, epinephrine, grow th horm one and
cortisol. Fifty percent of endogenous insulin is removed by the liver with most of
the remaining insulin excreted by the kidneys.

The insulin receptor consists of 4 protein subunits, 2 a and 2 3- It is proposed
that 2 insulins bind to the 2 a -subunits of the insulin receptor resulting in
autophosphorylation of tyrosine sites on the 2 3-subunits. The tyrosine kinase
activity catalyzes the phosphorylation of serine kinases or phosphoprotein
phosphatases, w hich phosphorylate or dephosphorylate ta rg e t enzym es
resulting in the alteration of m etabolic pathways typical of insulin action.

In

contrast, the glucose transporter is not phosphorylated in response to insulin
and the transporter is translocated to the plasma membrane to take up glucose.
C e llu la rly ,

in su lin

s e c re tio n

is

s tim u la te d

w hen

in tra c e llu la r

concentrations increase due to depolarization of a resting cell.
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glucose from the blood by preventing the liver from releasing additional glucose
and by enhancing glucose transport into muscle and fat cells.

There are 5 known glucose transporters. They are term ed GLUT 1-5. These
different transporters are located in different tissues and differ in term s of the
glucose requirements of each tissue. Some transporters are found in the same
tissue. GLUT 1 and GLUT 3 transporters are found in most tissues; w hereas
GLUT 4 is found primarily in muscle and fat; GLUT 2 is found in liver; and GLUT
5 is found in the small intestine and kidney.

There is a 20 fold increase in

glucose transporters when muscle and fat are exposed to insulin. This involves
recruitment of transporters from the cytoplasm to the surface and increases in
the m axim um transport capacity of those already there.

To enter the cell,

glucose first occupies its binding site on the outside of the cell.

Next, the

glucose molecule with its transporter change conformation so that the glucose
now occupies the binding site that faces into the cell.

The transporter then

releases the glucose into the cytoplasm and then changes its conform ation to
face outward again (Lienhard et al., 1992).

1.4

Insulin Resistance

Insulin resistance occurs when the pancreas m akes insulin, but fo r som e
reason the insulin is not very effective at promoting the transport of glucose from
the blood into the cells of the body. There are many who believe that insulin
resistance is due to a specific insulin-receptor gene defect. Some believe that
this insu lin -re cep to r m utation contributes to insulin resistance in a sub
population of NIDDM patients (O’Rahilly et al., 1991; Cocozza et al., 1992; Kim
et al., 1992). Insulin resistance has also been implicated in a num ber of other
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disorders such as obesity, essential hypertension, lipid abnorm alities and
a th e ro scle ro tic c a rd io v a s c u la r disease
Ferranninni, 1991).

(R eaven,

1988;

D eF ron zo

and

Although genetic defects have been im plicated in som e

cases of insulin resistance, it is believed that most insulin resistance occurs at
the postreceptor level (Clauser et al., 1992).

There are three types of insulin resistance:

prereceptor (involving insulin

structure, degradation or function), receptor defects (defects of insulin receptors
at the surface of cells) and post receptor insulin resistance (Kahn, 1985).
Mechanisms for prereceptor insulin resistance include mutation of the insulin
gene, increased degradation of insulin and formation of anti-insulin antibodies
which block insulin's action.

Defects in insulin receptors include decreased

num bers of receptors, decreased affinity of the receptor for insulin or defective
tyrosine kinase.

There are currently several animal models used to study insulin resistance. The
first animal used to study this phenomenon was the mouse.

These m ice are

obese and diabetic. There are three strains of mice including C57BL/GJ obese
(ob), KK mice and their hybrids, C57BL/Ks (db) and the NZO (New Zealand
obese) mouse.

Rats with concurrent diabetes and obesity include the Zucker

fatty (fa). Diabetic fatty (ZDF/Drt-fa), Wistar-Kyoto diabetic and W istar-Kyoto fatty.
A new er strain of rat used to study diabetes is the corpulent S H R /N -cp with
nephropathy, the SHHF/Mcc-cp with congestive heart failure, and the Jcr;LA-cp
w ith ischaem ic c a rd io va scu la r disease.

C orp ule nt strain s te n d to be

hypertensive diabetic rat strains. There are other more obscure models to study
insulin resistance and/or other NIDDM-like syndromes.

However, the models

m entioned offer sym ptom s believed to m ost closely sim ulate hum an NIDDM.
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Animal models of NIDDM are reviewed in two recent papers (Shafrir, 1992 and
Bailey and Flatt, 1993).

1.5

Drug Therapy for NIDDM

Most NIDDM patients can be treated successfully without drugs. Initial therapy
is always diet, exercise and education.

This is particularly true for the patient

who is obese since insulin resistance can be caused by obesity. W eight loss
and exercise are both associated with a decrease in insulin resistance.

The

prim ary aim in treating diabetes is to relieve symptoms, improve, quality of life
and

p re ve n t

both

a cu te

and

c h ro n ic

c o m p lic a tio n s

(R ifk in ,

1988).

Hyperglycemia has been associated with chronic diabetic complications in both
anim al and human studies.

However, this is not alw ays the case.

Some

patients with poor control never develop com plications (Pirart, 1978).

Since

insulin resistance and im paired insulin secretion are key factors in the
pathogenesis of NIDDM, treatment should be directed at restoring intermediary
metabolism towards normal by improving insulin secretion and reducing insulin
resistance (Gerich, 1989).

1.5.1

Sulfonylureas

There are five com m ercially available sulfonylureas in the United States. They
all consist of a sim ilar sulfonylurea core with different arom atic and alkyl
substituents that produce pharmacokinetic and pharmacologic differences. The
sulfonam ide group is essential for hypoglycem ic action (Loubatieres, 1944).
This class of drugs is further subdivided. The first generation drugs, discovered
in the 1960’s, consist of tolbutam ide, tolazam ide and chlorpropam ide.
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second generation drugs, discovered in the 1970's, consists of glipizide and
glyburide.

Three quarters of the hypoglycemic market from 1964 to 1986 was

accounted for by three drugs:

chlorpropam ide, glyburide and g lip izid e

(Kennedy et al., 1988). Tolbutamide causes the fewest serious side effects of
all the sulfonylureas; however, it is the shortest-acting and least potent.
Chlorpropamide is the longest acting and causes the most serious side effects,
among which hypoglycemia and severe hyponatremia are the most significant.
Glipizide and glyburide, the most potent of the available agents, are 100 to 150
times more potent than tolbutamide.
O

CH3

SOg— NH —C -

NH^

T O L B U T A M ID E

Cl

—6^

o
II

SO2— N H - C -

NH

C H L O R P R O P A M ID E
O

S N

G L Y B U R ID E
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Sulfonylureas stimulate the release of insulin by increasing beta-cell sensitivity
to glucose so that more insulin is released at every glucose level, but they do
not increase the synthesis of insulin (Grodsky et al., 1977). It appears that all of
the sulfonylureas have a sim ilar mechanism of action. A sulfonylurea receptor
has been found on the p cell and may be closely linked to or part of an ATPsensitive potassium-ion channel.

Inhibition of the efflux of potassium ions by

sulfonylureas may lead to depolarization of the p-cell membrane and the entry
of calcium which activates protein kinase C associated with exocrine secretory
granules (Oberwetter et al., 1987; Zawalich et al., 1988) resulting in exocytosis
of insulin-containing secretory granules. These drugs are ineffective in patients
w ithout functional p-cells (IDDM); however, some patients w ill experience
d e c re a s e s

in

g lu c o s e

c o n c e n tra tio n s

d e s p ite

u n c h a n g in g

in s u lin

concentrations, indicating an increase in insulin receptor binding or insulin
tissue sensitivity.

Along with decreased plasma glucose, sulfonylureas are known to decrease
total plasma cholesterol, total triglyceride, and VLDL triglyceride and cholesterol
w ith e ith e r no change (Taskinen et al.,

1986) or a m odest incre ase

(Moorehouse, 1967) in HDL levels.

One of the problem s with the use of sulfonylureas is the p ossib ility of
hypoglycemic episodes; another is that their use has not been associated with a
decrease in cardiovascular complications of NIDDM. An additional problem is
that approxim ately one th ird of NIDDM patients do not at firs t achieve
satisfactory glycémie control with these drugs. The main reason for the failure is
lack of dietary com pliance (Melander, 1988) and severely impaired islet p-cell
function (Rendell, 1983).

Five to ten percent of those patients achieving
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glycémie control have secondary failure after 10 years of treatm ent with these
drugs.

O ther common side effects include gastrointestinal, hem atologic, and

dermatologie reactions in less than 2 percent of patients.

1.5.2 Biguanides

Buformin, phenformin and metformin comprise this chemical class of drugs and
are not marketed in the United States. Metformin is widely used in Europe and
C anada, w here it accounts fo r 25 percent of the p rescriptions fo r oral
hypoglycem ic agents (Bailey and Nattrass, 1988).

These com pounds are

d ifferent from first generation sulfonylureas in that they do not undergo
biotransform ation, are elim inated solely by the kidney and are not bound to
plasma proteins.

NH

NH

V

Tf

NH
P H E N F O R M IN
NH

^"3^N ^
/

NHo
NH

NH
NH

A

NH,

CH3

M E T F O R M IN
Biguanides contain two linked guanidine molecules. These com pounds lower
blood glucose concentrations by producing insulin-like effects on skeletal
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muscle, liver, kidney and fat (Hermann, 1979), the exact mechanism of action
being unknown.

It is known that they suppress hepatic gluconeogenesis,

stim ulate glycolysis, and inhibit glucose absorption from the intestine (Jackson
et al., 1987).

These agents do not stim ulate insulin secretion and are only

effective in patients with some endogenous insulin. Biguanides are reported to
not cause hypoglycemia.

Interestingly, a recent report states that m etform in

Im proves cardiac function in isolated STZ-diabetic rat hearts (Verm a and
McNeill, 1994).

Some reports suggest that these com pounds cause lactic

acidosis, but in the 20 years of Metformin use In Canada, there have been no
cases of lactic acidosis reported (Vigneri and Goldfine, 1987). Phenformin, on
the other hand, was discontinued in 1977 in the United States due to several
deaths attributed to lactic acidosis.

1.5.3 Insulin Sensitizers

It was previously indicated that one of the worst side effects of sulfonylurea use
is severe hypoglycemia resulting from over-stimulation of insulin secretion. This
suggests that th e

d eve lop m e n t of oral

h ypo glyce m ics

w hich

co ntro l

hyperglycem ia w ithout stim ulating insulin release would be an attractive
alternative. A second pharmacotherapeutic option to treat NIDDM would be to
restore tissue sensitivity to insulin.

Two chem ically distinct groups of agents

have been synthesized which may accomplish this task, vanadyl sulfate (and its
derivatives) and the thiazotidinediones. Insulin sensitizers are com pounds that
mimic the actions of insulin or increase tissue sensitivity to insulin. One such
com pound, vanadyl, has been shown to possess insulin-like properties in
various cellular models such as isolated adipocytes, myocytes and hepatocytes
(Tolman et al., 1979; Dubyak et al, 1980; Clark et al, 1985; Duckworth et al.
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1988; Jackson et al., 1988; Gomez-Foix et al., 1988). This compound is able to
stim ulate glucose transport, inhibit glycogenolysis and inhibit lipolysis.

Its

mechanism of action is still unclear, but it has been suggested that it might work
by Inhibiting phosphotyrosyl-protein phosphatases (Sw arup et al., 1982),
inducting tyrosine phosphorylation (Tamura et al., 1984; Gherzi et al., 1988;
Tracey et al., 1986), activating glucose transport through activation of the
GLUT4 transporter gene (Strout et al., 1990), translocating the transporter from
the cellular organelles to the plasm a m em brane (Paquet et al., 1990), or
increaseing intracellular calcium secondary to Ca-Mg-ATPase inhibition (Delfert
and McDonald, 1985).

o=v

O — S—

OH

V A N A D YL SULFATE
CH,

CH3

B IS (M A L T O L A T O )O X O V A N A D IU M

(IV )
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Vanadyl's anti-diabetic activities were first dem onstrated by Heyliger et al. in
streptozotocin (STZ)-treated rats, a model of IDDM with some properties in
com m on

w ith

o rth o va n a d a te ,

NIDOM

(1985).

a d m in iste re d

In th ese
in

d rin kin g

studies,
w ater,

0.8

w as

m g/m l sodium
able

to

co n tro l

hyperglycem ia and prevent the im pairm ent of cardiac function w ithout any
change in plasma insulin levels in diabetic rats, but decreased levels in controltreated rats. This suggests that insulin secretion is not related to the activity of
vanadium , but that it replaces or potentiates endogenous insulin.

It was

interesting to discover that vanadate prevented insulin-resistance in STZinduced diabetic rats (Blondel et al., 1989) and ob/ob genetically obese mice
(Brichard et al., 1990) and corrected blood glucose in BB spontaneously
diabetic (type I) rats (Ramanadham et al., 1990).

Vanadyl sulfate and other related com pounds, bis(m olatolato)oxovanadium
(BMOV) and naglivan, work by a sim ilar mechanism of action to reduce insulin
resistance and restore euglycem ia.

BM OV reduces insulin resistance and

norm alizes plasm a glucose levels in S TZ-diabetic rats and im proves the
diabetic pathology observed in non-treated diabetic rats relative to non-diabetic
rats (Dai et al., 1993). Similarly, v a n a d y l's actions mimic insulin by increasing
glucose tra n s p o rt in adipose and m uscle tissu es,

incre asin g
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m etabolism , activating glycogen synthesis and inhibiting the breakdow n of
triglycerides.

In addition, it has been shown that vanadyl can reduce non

diabetic plasma insulin levels without affecting plasma glucose.

This im plies

that vanadyl works by potentiating insulin's action (Ramanadham et al., 1989).

V anadium has som e reported toxicity, p articula rly d ig e stive intole ra nce
(diarrhea) leading to dehydration and death of animals.
few er toxicity problems.

Vanadyl sulfate has

This compound exhibits the same glucose lowering

effects and after chronic treatment, the effects can still be seen 13 weeks after
cessation of treatment (Ramanadham et al., 1989). It is doubtful that this is due
to accumulation in tissues since the blood and kidney levels (main depot sites)
were barely detectable (Ramanadham et al., 1989).

Given vanadyl's effectiveness at lowering plasma glucose and reversing insulin
resistance, it has been proposed as a potential therapy in human diabetes in
general, and in insulin-resistant states in particular (Cros et al., 1992). Vanadyl
has the ability to prevent the myocardial and metabolic abnorm alities seen in
diabetic rats during treatment as well as 13 weeks after withdrawal from vanadyl
(Ramanadhan et al., 1989).

It has been suggested that this effect is due to

normalization of plasma insulin levels and that insulin has a positive inotropic
effect in the heart (Ramanadhan et al., 1989).

1.5.4 Thiazolidinediones

The m ost recent chem ical class of oral hypoglycemics to be introduced is the
th ia z o lid in e d io n e s

(5 -(4 -a lk o x y b e n z y l)-2 ,4 -th ia z o lid in e d io n e s ).

T h e se

com pounds appear to reduce insulin resistance or potentiate insulin action in
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genetically diabetic and/or obese anim als (Sohda et al., 1992), but do not
induce hypoglycemia. The presence of a pyridyl ring on the p-alkoxy chain of
the benzyl moiety is necessary for biological activity. Another Im portant factor
for activity is the location of the pyridine nitrogen a to the oxyethyl chain (Sohda
et al., 1992). It has also been reported that the 4-oxybenzyl group and the 2,4thiazolidinedione m oiety are necessary for hypoglycem ic and hypolipidem ic
activities (Momose et al., 1991), respectfully.

CH,
NH

C IG L IT A Z O N E

O

NNa
E N G L IT A Z O N E

CH

CH3

.jCO-'
T R O G L IT A Z O N E
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Given the known effects of this class of drugs, it appears that the prim ary effect
of these drugs is to improve peripheral target tissue responses to insulin. It has
been suggested that these effects are due to enhanced post-binding events
m ediating insulin action (Hofmann and Coica, 1992).

One exam ple is the

demonstration of increased GLUT 4 glucose transporter expression. This was
observed in epididymal fat pads of insulin resistant KKAV mice after treatm ent
with pioglitazone (Hofmann et al., 1991). This effect was seen only in anim als
where insulin was present (NIDDM) (Hofmann et al., 1991), supporting the
hypothesis of an amplified insulin signal.

The first of these com pounds to be synthesized in large quantities was
c ig lita z o n e , 5-[4-(1-m ethylcyclohexylm ethoxy)benzyl]thiazolidine-2,4-dione,
(AD-3878, U-63,287).

It was discovered by scientists at Takeda Chem ical

Industries, Ltd., of Osaka, Japan, (Sohda et al., 1982; Fujita et al., 1983). This
com pound

n o r m a liz e s

h y p e rg ly c e m ia ,

h y p e r in s u lin e m ia

and

hypertriglyceridem ia in various animal m odels of insulin resistance (Fugita et
al., 1983; Chang et al., 1983) including KKAY mice (Ikeda et al., 1990; Fujiwara
et al., 1988), W istar Fatty rats (Ikeda et al., 1981) and ob/ob mice (Fujiwara et
al., 1988; Stevenson et al., 1990).

This com pound requires a dose of 100

mg/kg/day to lower glucose in ob/ob and db/db mice (Chang et al., 1983).
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T ro g lita z o n e , (CS-045), [(±)>5-[4-(6-hydroxy-2,5,7,8-tetram ethylchrom an-2-ylm e th o x y )b e n z y l]-2 ,4 -th ia z o lid in e d io n e ]
thiazoiidinedione group.

is

a n o th e r

com pound

in

th e

In animal experim ents using insulin resistant Zucker

Fatty rats, it was determined that 150 mg/day p.o. of this com pound improved
glucose tolerance and decreased insulin levels after oral glucose loading due
to increasing insulin responsiveness (Fujiwara et al., 1988).

It w as also

dem onstrated that troglitazone increased insulin binding, increased insulin
receptor num bers in adipocytes and enhanced both insulin sensitivity and
responsiveness (Fujiwara et al., 1988). Along with these effects, troglitazone
decreased plasm a lactate, free fatty acids and ketone body levels w ithout
decreasing food intake or body w eight (Fujiwara et al., 1988).

This is an

important finding since it has been suggested that body weight loss improves
glucose tolerance and that this is what causes the glycémie improvements.

In

all studies conducted with this compound, mean body weight did not change
suggesting that improved glucose tolerance is not due to body w eight loss in
patients.

In the first clinical study with troglitazone, 204 patients were given either 200 or
400 mg per day either alone or in combination with sulfonylureas. Kuzuya and
coworkers were able to find a dose-dependent glucose lowering effect with
25% efficacy with 200 mg/day and 46% efficacy with 400 mg/day (Kuzuya et al.,
1991).

They also found that the drug was as effective with or w ithout the

addition of sulfonylureas. This suggests that troglitazone works by a different
m echanism than that of the sulfonylureas.

These researchers found som e

adverse effects associated with the drug including gastrointestinal problem s
(6%), decreased red blood cell count (3.5%) and increased LDH levels (6%)
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(Kuzuya et al., 1991). In other clinical studies using the same 400 m g/day dose,
it was determ ined that hemoglobin A ic was also decreased (Iwam oto et al.,
1991) and that the use of this drug was associated with significantly increased
HDL-cholesterol levels (Suter et al., 1992).

Suter was able to determ ine that

the increased HDL is comparable to that achieved with lipid-lowering drugs in
hyperlipidémie patients (Frick et al., 1987). The inverse relationship between
plasm a H D L-cholesterol co nce ntra tion s and c a rd io va scu la r risk is w ell
established; this compound would be useful in those NIDDM patients at high
risk of developing cardiovascular complications.

E n g lit a z o n e

(C P -68722), [( ± .)- 5 -[( 3 ,4 - d ih y d r o -2 -p h e n y fm e th y l-2 H -1 -

benzopyran-6-yl)m ethyl}thiazolidine-2,4-dione, is another com pound in this
class.

This compound, given at a dose of 5-50 m g/kg/day to ob/ob mice,

showed a dose-dependent glucose and insulin lowering effect and decreased
free fatty acids, glycerol, triglycerides and cholesterol after 11 days of treatment,
but not after a single dose (Stevenson et al., 1990). It also reversed the defects
in Insulin-stimulated glycolysis and glycogenesis and basal glucose oxidation
in isolated soleus m uscle with no hypoglycem ic effects seen in either the
treated control or diabetic groups (Stevenson et al,, 1990).

This com pound

appears to be able to norm alize plasm a glucose at lower doses than either
ciglitazone or troglitazone.

In studies using 3T3-L1 adipocytes, englitazone overcam e insulin resistance
primarily by increasing Vm ax of 2-deoxyglucose uptake. Like insulin, it appears
to stim ulate glucose uptake by a m echanism that involves translocation of
intracellular glucose transporters to the plasma membrane and de novo protein
synthesis since the uptake of glucose could be inhibited by protein synthesis
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inhibitors and was temperature dependent (Kreutter et al., 1990). These effects
are greater and require lower doses than those seen with sulfonylureas.
Interestingly, sulfonylureas require insulin to exert their full effect. Sulfonylureas
alone can induce the expression of glucose transporters, but require insulin for
translocation to the cell membrane (Wang et al., 1989).

Englitazone can do

both independent of insulin. This suggests it might be an insulinomim etic rather
than a true sensitizer.

The other thiazolidinediones have not been tested for

this.

P io g lita z o n e , (5-[4 -[2 -(5 -e tyl-2 -p yrid yl)e th o xy]b e n zyl]-2 ,4 -th ia zo lid ln e d io n e
(AD-4833), the final member of this class of drugs, has been studied extensively
for its glucose and lipid lowering effects in anim als.

There have been no

studies concerned with the potential beneficial or deleterious cardiovascular
effects of the drug.

These are concerns regarding clinical use since

pioglitazone has been reported to cause cardiac enlargem ent at doses
considered therapeutic (CoIca, J., personal com m unications).

As with other

com pounds of the th iazo iid ine dio ne drug class, p io glitazone

corrected

abnormalities in glucose, lipids and insulin in KKAY mice (2.4-24.5 mg/kg/d for 4
days) and Zucker fatty rats (0.1-10 mg/kg/d for 4 days) (Ikeda et al., 1990). As
seen with the other thiazolidinediones, pioglitazone lowered plasm a glucose
and lipids in obese animals, but not in lean or STZ-diabetic rats, suggesting that
the lipid and glucose lowering effects are associated with reduced insulin
resistance and enhanced insulin action on peripheral tissues (Ikeda et al.,
1990).

When ED25 values were com pared in KKAY mice, pioglitazone was

much more potent (6 mg/kg/d) than was ciglitazone (31 mg/kg/d) (Ikeda et al.,
1990).

The ability of pioglitazone to decrease plasm a glucose, insulin,

triglycerides and fatty acids is dose dependent as is its prom otion of body
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weight gain (the higher the dose, the greater the absolute weight gain) (Ikeda et
al., 1990).

Pioglitazone, when given at a dose of 3 mg/kg/day for 6 days, has been shown
to decrease insulin resistance in peripheral tissues and livers of W istar fatty rats,
while having no effect on the lean litter mates (Sugiyama et al., 1990a). This
was determined by the observation that pioglitazone restored hepatic glycogen
production and peripheral glucose utilization in the presence of infused insulin
in fatty rats.

In addition, glucose-6-phosphatase decreased and glucokinase

increased, suggesting an increased response of the liver to insulin and a
resulting suppression of hepatic glucose production (glyco lytic p athw ay
becomes dom inant against gluconeogenic pathway).

These findings suggest

that pioglitazone also reduces insulin resistance via hepatic enzyme regulation
(Sugiyama et al., 1990a).

These studies also indicate that pioglitazone can

norm alize plasm a glucose levels at a much low er dose than th e other
thiazolidinediones.

In addition to the effects on liver insulin resistance, it was determ ined that
pioglitazone increased insulin-stim ulated glycogen synthesis and glycolysis in
the isolated soleus m uscle and insulin stim ulated glucose oxidation and
lipogenesis in adipocytes without any effect on insulin binding (Sugiyama et al.,
1990b). Vanadate, the insulinomimetic, which is known to work at post receptor
binding sites, was potentiated by pioglitazone, suggesting that the glucose and
lipid lowering effects of the drug are caused by reducing insulin resistance at
post-receptor binding sites (Sugiyama et al., 1990b).
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P ioglitazone has been shown to inhibit cholesterol absorption and to low er
plasma cholesterol concentrations in cholesterol-fed rats (Coica et al., 1991).
These effects only occur when insulin is present, working synergistically to
lower absorption of cholesterol and circulating cholesterol and triglycerides
(Coica et al., 1991). It has been suggested, given the aforem entioned results,
that treatm ents that improve insulin sensitivity may also have a positive impact
on coronary artery disease associated with diabetes.

Although the plasm a

cholesterol levels in rats not fed a high cholesterol diet did not change, the
lipoprotein profiles were different.

In KKAY mice, the m ajority of plasm a

cholesterol is carried in HDL and HDL levels are very high (Castle et al., 1993).
Pioglitazone is known to lower elevated lipids in other anim al m odels such as
insulin resistant obese Rhesus Monkeys and although the exact mechanism is
unknown, it does enhance triglyceride clearance rate (Kem nitz et al., 1994)
possibly through stimulation of lipoprotein lipase or triglyceride lipase.

As m entioned earlier, GLUT4 glucose transporters are m em brane proteins
expressed only in tissues in which glucose uptake is regulated by insulin (fat,
skeletal muscle and heart). In fat and muscle insulin stim ulates glucose entry
by recruiting glucose transporters from intra cellu la r pools to the plasm a
membrane (Cushman and Wardzala, 1980). GLUT4 expression is decreased
in KKAY mice. Pioglitazone corrects the GLUT4 transporter defect (Hofmann et
al., 1991). This seems to be more prominent in fat than muscle and requires the
presence of insulin. GLUT2 transporters, the m ajor liver glucose transporters,
re m a in e d

unchanged

by

p io g lita z o n e

p h o sp h o e n o lp yru va te ca rb o xykin a se

tr e a tm e n t;

(a m a jo r rate -lim itin g

however,
enzym e

fo r

gluconeogenesis) activity, w hich is elevated in untreated d iabetics, w as
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normalized, suggesting that pioglitazone restored sensitivity to insulin's norm al
inhibitory actions (Hofmann et al., 1992).

To further determine the mechanisms by which pioglitazone decreases insulin
resistance, insulin receptor kinase levels were evaluated. Pioglitazone caused
no change in receptor binding in W istar fatty rats, but increased insulinstimulated autophosphorylation of insulin receptors to 78% over the level in the
control (Kobayashi et al., 1992).

Kinase activity affecting the exogenous

substrate poly G lu^Tyr^ also increased to 87% over control obese rats. Lean
ra ts

tre a te d

w ith

p io g lita z o n e ,

h o w e v e r,

show ed

no

change

in

autophosphorylation and kinase activity (Kobayashi et at., 1992). These results
suggest that pioglitazone increased insulin sensitivity in part by activating the
kinase of its receptors through indirect effects on insulin receptors.

It was

suggested that if the conform ational change occurs when insulin binds to its
receptor, pioglitazone may potentiate the change to activate kinase or signal
transduction between the two subunits of the receptor (Kobayashi et al., 1992).
This effect was seen in the skeletal muscle of rats fed a high fat diet (Iwanishi
and Kobayashi, 1993).

These cum ulative results suggest that pioglitazone's

ability to decrease insulin resistance may result from improving the sensitivity of
target tissues to insulin rather than from a direct corrective action of the agent on
glucose transporters (Hofm ann et al, 1991).
pathw ay o th e r th an

It could be acting through a

a ctivatin g tyro sin e kinase

in the in su lin -sig n a lin g

m echanism and the increased kinase activity may reflect only a secondary
effect of metabolic improvement (Iwanishi and Kobayashi, 1993).
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1.6

General Hypothesis

A new chem ical class of antidiabetic agents, th e th ia zo lid in e d io n e s, by
correcting or preventing insulin resistance in g en etica lly d ia b etic anim al
models, can cause physiologic or metabolic changes that may reduce the risk of
developing one or more cardiovascular complications of type II diabetes.

1.7

Objectives

1.

To determine the ability of pioglitazone, a thiazoiidinedione, to prevent or

correct (reverse) diabetic hyperglycem ia in 3 sets of g enetically diabetic
(NIDDM) rats known to exhibit a phase of hyperinsulinemia (insulin resistance).
To fulfill this objective, plasma glucose (every tw o weeks), insulin (every two
weeks) and glycosylated hemoglobin (at termination) were determined.
a.

Administered prior to onset of hyperglycemia (vs. no drug) —
In young ZD F rats (7 weeks of age at initiation of treatment)

b.

Administered after onset of hyperglycemia (vs. no drug,
hydralazine and vanadyl) - In older ZDF rats (13 weeks of age at
initiation of treatment)

c.

Administered prior to onset of hyperglycemia diabetic rats which
may be prone to develop hypertension or congestive heart failure
(vs. no drug, hydralazine and vanadyl) — In young ZDF/SHHF rats
(6 weeks of age at initiation of treatment)

2. (a,b,c)

To determ ine if the prevention or correction of hyperglycem ia by

pioglitazone is paralleled by corrections in plasm a triglycerides, cholesterol,
lipoproteins or free fatty acids, elevations of which may be associated with
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enhanced rates of atherogenesis and whether pioglitazone causes favorable or
unfavorable effects on HDL cholesterol.

3. (a.b.c)

To determ ine w hether cardiovascular abnorm alities exist in the

animal models of insulin resistance listed in objective 1, and w hether correction
of insulin resistance with pioglitazone is associated with beneficial changes in
the following cardiovascular parameters:

heart size and heart weight vs. body weight ratios
i.

cardiac lipid profiles: cholesterol and triglycerides

ii.

aortic (vascular) sensitivity

V.

cardiac performance

4. (b,c)

To evaluate the usefulness of ZDF or ZDF-SHHF rats as models of

hypertension associated with NIDDM and to assess the potential of pioglitazone
or other thiazolidinediones to treat hypertension by altering the state of insulin
resistance.
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2 .0

M ETHODS

2.1

Study Groups

Study la , 2a, and 3a were conducted using tw enty-four young male Zucker
Diabetic Fatty Rats (ZDF, Drt-/a), obtained from Genetic Models, Indianapolis,
Indiana, and twenty-three male, non-diabetic, Zucker Lean Rats (ZL) littermates.
These groups w ere each divided into tw o sub-groups: one received 10
mg/kg/day pioglitazone MCI suspended in sodium citrate, adm inistered by oral
gavage, while the other group received the vehicle (0.5 M sodium citrate). The
subdivision of animals resulted in four groups which will be designated control
(GU, n = 11), control treated (CP, n=12), diabetic (DU, n=12), and diabetic treated
(DP, n=12).
d e riv e d

Diabetes was not chem ically induced, rather, these genetically

n o n -in s u lin -d e p e n d e n t-d ia b e tic

ra ts

b e ca m e

s p o n ta n e o u s ly

hyperglycemic between 7 and 10 weeks of age. Treatm ent was initiated in all
groups of rats at 7 weeks of age and continued for 6 weeks to a final age of 13
weeks at study termination. Diabetic rats were housed individually in hanging
metal cages and lean rats were housed in shoebox cages. They were housed
in a 12 hour light-dark cycle environm ent and received food (Purina 5008 rat
chow) and water ad libitum. All animals were allowed a minimum of 5 days to
acclimate before initiation of experiments.

Studies 1b, 2b, 3b and 4b used the same animal model (ZDF rats), however,
the rats used were of an older age. Treatment was begun when they were 13
w eeks of age (rather than 7) having fully established hyperglycem ia and
continued 8 weeks rather than 6 , ending at 21 weeks of age. This study also
involved additional treatm ent groups. Along with pioglitazone treated anim als
30
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(10 m g/kg/day) and vehicle treated control anim als, one group of anim als
received vanadyl (increm ental dosages from 0.05 m g/m l to 0.75 m g/m l
adm inistered in deionized drinking w ater ad libitum ) and a n o th e r group
received hydralazine (5 mg/kg twice daily by oral gavage). The subdivision of
animals resulted in 8 groups, which were designated control (CU, n=5), control
treated (CP, n=5), diabetic (DU, n=5), diabetic treated (DP, n=5), control
hydralazine (CH, n=4), diabetic hydralazine (DM, n=4), control vanadyl (CV,
n=5) and diabetic vanadyl (DV, n=5). Initially DH and CH began with 5 rats, but
one rat in each group died. Ttiese rats were housed identically to the first group
of rats, but were fed

Purina 5015 rat chow which Is higher in fat.

Studies 1c, 2c, 3c and 4c consisted of a young hybrid animal model. These rats
are a hybrid betw een the ZD F m odel and the SH H F (sp o n ta n e o u sly
hypertensive) animal models.

Treatm ent was begun at 6 w eeks of age and

continued for 8 weeks to age 14 w eeks at term ination.

The subdivision of

animals resulted in 8 groups which will be designated control (CU, n=7), control
treated (CP, n=7), diabetic (DU, n=7), diabetic treated (DP, n=7), control
hydralazine (CH, n=4), diabetic hydralazine (DH, n=4), control vanadyl (CV,
n=4) and diabetic vanadyl (DV, n=4). Lean rats were housed in m etal hanging
cages and diabetic rats in shoebox cages, as in the other studies, and received
the same regular rat chow as in studies la , 2a, and 3a.

2.2

Drug Therapy

Pioglitazone hydrochloride was provided by Jerry Coica, Ph.D., Upjohn Co.,
(Kalamazoo, Ml) and was suspended in 0.5 M sodium citrate (Sigma, St. Louis,
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MO), pH 4.5, by homogenization with a Biohom ogenizer (M 133/1281-0, Fisher
Scientific, Fair Lawn, New Jersey), before administration to rats by oral gavage
at a dose of 10 mg/kg/day. In study la , 2a, and 3a, dosages were calculated
and adm inistered each day at 2:00 pm.

In the other studies, drugs w ere

administered at approximately 8:00 am daily. An equivalent volume (1 ml/kg) of
sodium citrate vehicle was administered as a vehicle control to the non-treated
animals via the same method for studies a and b.

Hydralazine, 5 mg/kg, (Sigma Chem ical Co., St. Louis, MO) was dissolved in
deionized water and administered twice daily (approximately 12 hours apart) by
oral gavage.

Vanadyl Sulfate (Eastm an Kodak Co., Rochester, NY) was dissolved in
deionized drinking w ater to reduce oxidation. The concentration was changed
every 3 (+) days from an initial concentration of 0.05 m g/m l to a final
concentration of 0.75 mg/ml which is known to correct IDDM. This approach
was used to minimize toxicity due to dehydration.

If an animal failed to drink

adequate amounts of fluid, the dosage was reduced for a day until the animal
rehydrated.

As an overt measure of drug toxicity, animals were observed on a daily basis to
ensure that no diarrhea was present and their body weights were recorded.
The animals were given w ater ad libitum and were fed regular rat chow, Purina
Chow 5008, Richmond, Indiana in a and c studies, but were fed Purina 5015 in
the b studies.
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All other chemicals for general lab use (buffers, etc.) were obtained from Fisher
Scientific Co., Fair Lawn, NJ.

2.3

Measurement of Plasma Components

Blood was removed from pentobarbital anesthetized rats at study term ination
through the abdom inal aorta using a 22 gauge needle attached to a 10 cc
plastic syringe, containing a small amount of the anticoagulant EDTA.

Blood

was centrifuged at 4°C for 10 minutes in a Beckman Model TJ-6 Centrifuge at
2000 rpm and the plasma was separated and distributed into several m icrofuge
tubes for plasma analyses.

Plasma analyses included glucose, cholesterol,

triglycerides, free fatty acids and insulin.

All plasma sam ples were stored at

-70°C for later analyses. Some term ination plasma samples were analyzed on
an autom ated chem ical analyzer (Hitachi) while m ost w ere analyzed using
common biochemical kits (see section 2.3.1).

Blood was also collected at week 0, 2, 4, 6 and 8 for time course evaluation of
plasma triglycerides, cholesterol and insulin.

These sam ples w ere obtained

through the tail vein by nicking the tail with a sterile scalpel and stroking the tail
to collect the blood in microfuge tubes containing EDTA. Blood was separated
and plasma stored at -20 ®C for later analyses.

2.3.1

Glucose, Triglyceride and Cholesterol Determinations

Blood glucose w as m easured w eekly on a One Touch II G lucose A nalyzer
(Johnson and Johnson Co., Milpitas, California) using One Touch test strips.
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For these samples, the blood was obtained from the tail.

These values were

determined weekly using this method on 5 hour fasted rats.

On weeks 2, 4, 6 and 8 , plasma glucose and triglycerides were determ ined
using Stanbio enzym atic colorim etric kits obtained from Fisher Scientific Co.,
Fair Lawn, NJ. Cholesterol was determined using a sim ilar procedure with kits
obtained from Sigma Chemical Co., St. Louis, MO. The standard procedure for
all of these kits was to use 10 |xt of plasma plus 1 ml of reagent and incubate for
10 m inutes followed by reading the optical density on a Bausch and Lomb
Spectrophotometer at 500 nm.

2.3.2 Free Fatty Acid Determinations

Free fatty acids from a and b studies were measured at study term ination using
a chloroform extraction technique followed by colorim etric determination of free
fatty acid levels following the methods of Buncombe,W W (1963), as modified by
Itaya, K, and Ui, M (1965).

For study c, a m icro-assay technique from

Boehringer Mannheim, Indianapolis, Indiana, was used.

Determ inations were

made at weeks 0, 4 and 8 .

2.3.3 Plasma Insulin Determinations

Plasma insulin was determined at weeks 0, 2, 4, 6 and 8 weeks. Plasma insulin
was measured using a double antibody radioimmunoassay obtained from Unco
(Linco Research Inc., St. Louis, MO) according to the method of Morgan and
Lazarow (1963).

This kit uses polyclonal antibodies raised in guinea pigs

against rat insulin (100% specific to rat insulin). The assay used
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insulin of specific activity 0.02 pCi per sample. The sensitivity of the assay as
used was 0.1 ng/ml. Intra and inter assay coefficients of variation w ere 1.34%
and 3.17%, respectively.

2,4

Measurements of Cardiac Function

Following six or eight weeks of oral drug treatm ent, the rats were overdosed
with Pentobarbital Sodium (Fort Dodge Laboratories, Inc., Iowa) 100 mg/kg i.p.
A fter loss of pain and righting reflexes, rats w ere exanguinated via the
abdominal aorta with a 10 ml plastic syringe and a 22 g needle.

The blood was

centrifuged and separated for later plasma analyses. During the exanguination
process, the heart was rapidly rem oved and placed into a dish of warm
Chenoweth-Koelle (OK) buffer for transport to the working heart apparatus. The
heart was first cannulated through the aorta, according to the Langendorff
procedure, and perfused with warm, oxygenated (95% O2 and 5% C O 2 ), OK
buffer (millimolar concentrations of: NaCi, 120; KOI, 5.6; C aC l2 , 2.18; MgCl2 ,
2.1 ; N aH C O s, 19.2; and glucose, 10).

O nce the pulm onary vein was

cannulated, the system was switched to an isolated working heart preparation.
This allows perfusion first through the left atria into the left ventricle and finally
out the aorta.

The buffer was not recirculated.

PE-10 tubing w as used to

provide resistance. The experiment involved subjecting the heart to changes in
preload and observing changes in cardiac performance. The criteria measured
were left ventricular developed pressure (LVDP), rate of force developm ent
(+dP/dT) and rate of relaxation (-dP/dT) as previously described (Rodrigues and
McNeill, 1986). At the completion of the working heart analysis, the whole heart
was w eighed to determ ine the heart weight to body w eight ratio then freeze
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clam ped In liquid nitrogen to preserve sam ples for subsequent determ inations
of myocardial triglyceride and cholesterol levels.

2.5

Blood Pressure

Blood pressure values were determ ined for each rat in study b and c.

This

method involves the use of a semi-automated, amplified tail cuff inflation device
from IITC Inc., W oodland Hills, Califom ia,

Rats were placed in appropriately

sized holders and sensors and allowed to acclimate to the surroundings for 2030 minutes. The tail inflation device containing a light sensor was subsequently
inflated to 300 mmHg and allowed to deflate in a linear fashion. The am plifier
transfers the signal from the sensor and translates it into a blood pressure trace
which is seen on the chart recorder. From this tracing, systolic blood pressure
can be m easured from the initial pulses on the trace and the m ean arterial
pressure is measured from the first maximum pulse. The diastolic pressure is
calculated from the systolic and mean pressures. The calculation is as follows:

D.P.= 3(mean)-systoiic
2
2.6

Vascular Reactivity

Endothelium dependent relaxation is believed to be impaired in IDDM, but is
questionably affected in NIDDM; thus a series of experiments was designed to
investigate this phenomenon in NIDDM by measuring aortic sensitivity. Aortic
sensitivity w as m easured by determ ining the ability of 4 mm aortic rings to
contract in the presence of norepinephrine. Aortic strips were taken from the
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region just distal to the aortic arch of the heart. A 4 mm strip was suspended in
a w ater jacketed tissue bath containing 25 ml of Krebs buffer (containing mM
concentrations of: NaCI, 118; KCI, 4.7; CaCl2, 2.5; NaHC0 3 , 25; KH2 PO4 , 1 2 ;
M gS0 4 , 1.2; Glucose, 11) and oxygenated with 95% O 2 and 5% CO2 at 37®C'
Two gram s of resting tension was placed on the strip to provide resistance
against which to contract. The tissue was held in place by two small fish hooks
w hich are attached to an F-60 M yograph Pressure T ra n sd u ce r (N arco
Biosystem s).

The contractions were translated by the coupling device and

produced a read out on the physiograph (Narco Biosystems).

The tissue was first allowed a 30 minute equilibration period. Then, to establish
w hether the tissue worked, the aortic strip was suspended in a high potassium
bath (40 mM KCI; replacing NaCI).

The tissue's ability to contract due to

depolarization of the m em brane indicated that the strip was w orking.

A

norepinephrine (NE) dose response curve was determ ined on each strip of
tissue using concentrations of NE from 10~9 M to 10"® M. Norepinephrine is an
alpha-adrenergic agonist in blood vessels which causes contraction of the
vascular tissue. Contractile force was expressed in grams.

2.7

Statistics

C om parison betw een group m eans w as accom plished using a one w ay
analysis of variance (ANOVA) followed by Scheffe's F-test, where applicable. A
probability of p<0.05 was used to indicate statistical significance.
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3.0

RESULTS

For the purpose of convenience, the legends in the fig ures have been
condensed to two letter acronyms for most treatment groups as follows:
CU

Control/ untreated rats

DU

Diabetic untreated rats

CP

Control pioglitazone

DP

Diabetic pioglitazone

CV

Control vanadyl

DV

Diabetic vanadyl

CH

Control hydralazine

DH

Diabetic hydralazine

NOTE:

Control refers to non-diabetic rats.

To review, the study groups are as follows:
a.

Administered prior to onset of hyperglycemia (vs. no drug) —
In young ZDF

b.

rats (7 weeks of age at initiation of treatment)

Administered after onset of hyperglycemia (vs. no drug,
hydralazine and vanadyl) — In older ZDF rats (13 weeks of age at
initiation of treatment)

c.

Administered prior to onset of hyperglycemia diabetic rats which
may be prone to develop hypertension or congestive heart failure
(vs. no drug, hydralazine and vanadyl) — In young ZDF/SHHF rats
(6 weeks of age at initiation of treatment)

3.1

Body Weights

Body weights of young (7-13 weeks of age) ZDF diabetic rats were significantly
greater than their non-diabetic littermates throughout the study. A fter one week
of oral treatm ent w ith 10 m g/kg/day pioglitazone HCI, body w eights w ere
38
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significantly higher than the untreated diabetic rats. Six weeks of pioglitazone
treatm ent caused a -1 .5 fold greater increase in body w eight relative to
untreated diabetics and -1 .8 fold increase over control rats. Non-diabetic rats
had a steady body weight increase whether given pioglitazone or not (FIG. 1).

Body w eights of older ZDF diabetic rats were significantly higher than non
diabetic littermates at 13 weeks of age. After 7 weeks of treatment (20 weeks of
age), body weight was not significantly different except in the vanadyl treated
group (FIG. 28).

Vanadyl lowered body w eights in both diabetic and non

diabetic older ZDF rats.

Pioglitazone and hydralazine had no effect on body

weight gain in the older ZDF rats (FIG. 2A.C).

At 6 weeks of age (before treatment) young hybrid ZDF/SHHF diabetic rats (DU,
DP) did not have elevated body w eights com pared to th e ir non-diabetic
littermates (CU). Unexpectedly, randomization of the control rats led to the CV
and CH groups beginning treatment at a lower body weight than either the CU
or DU groups. After 3 weeks of pioglitazone treatm ent (9 weeks of age) body
weights of the DP group were significantly elevated compared to DU and by the
end of the 8 weeks of treatment, DP was -1 .2 5 fold greater than DU (FIG. 3A).
There w as no effect on body w eight observed in the non-diabetic group
following pioglitazone treatment. Also at 9 weeks of age, the body w eights of
the DU group becam e significantly elevated com pared to the CU group and
remained elevated throughout the rest of the study. CU body weights exceeded
those of the CV and CH rats throughout the study.

Vanadyl significantly

decreased body w eight in the diabetic group after 8 w eeks of treatm ent.
Hydralazine had no effect on body weight in either diabetic or non-diabetic rats
(FIG. 3B,C).
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FIG. 1 Time course of oral pioglitazone effect on body weight in young ZDF
diabetic rats and non-diabetic littermates. Data represent the means
± SEM. Error bars sm aller than symbols are not shown.
#, significantly different from diabetic untreated from this point through w eek 13.
*, significantly different from control untreated from this point through week 13.
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FIG. 2. Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on body weight in older ZDF diabetic rats and non-diabetic littermates.
Data represent the means ± SEM. Error bars sm aller than symbols are not
shown. #, significantly different from diabetic untreated. *, significantly
different from control untreated.
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FIG. 3. Tim e course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on body weight In young hybrid ZDF/SHHF diabetic rats and non
diabetic littermates. Data represent the means ± SEM. Error bars sm aller than
sym bols are not shown. #, significantly different from diabetic untreated from
this point through 14 weeks of age. *, significantly different from control
untreated from this point through 14 weeks.
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3 .2

Plasm a Glucose

Fasting plasm a glucose levels of 7 w eek old young ZD F rats w ere not
significantly different from levels in control rats. By 9 weeks of age, DU plasma
glucose levels were significantly elevated relative to those of CU and CP rats.
Fasted plasm a glucose levels were significantly reduced by pioglltazone in
young ZDF diabetic rats beginning near the tim e of developing hyperglycem ia.
After tw o w eeks of treatm ent with pioglltazone, glucose levels of diabetic rats
w ere

c o m p le te ly

n orm a lize d

and

rem ained

so th ro u g h o u t th e

study.

Pioglltazone had no effect on the blood glucose in non-diabetic sham treated
rats (given 1ml/kg/day of 0.5 M sodium citrate by oral gavage) (FIG.4).

At 13 weeks of age, older ZDF diabetic rats had significantly elevated plasma
glucoses com pared to control rats.

O lder ZDF diabetic rats, that exhibited

consistent hyperglycem ia, showed no effect from pioglltazone treatm ent on
plasm a glucose at any point during the 7 w eeks of treatm ent (FIG. 5A).
However, vanadyl significantly decrease plasm a glucose after two weeks of
treatm ent with the drug (FIG. 58). During this period of time, rats were subjected
to steadily increasing concentrations of vanadyl from 0.05 mg/ml to 0.75 mg/ml
to avoid toxicity.

Hydralazine had no effect on plasma glucose (FIG. 5C).

Pioglltazone, vanadyl or hydralazine had no effect on plasma glucose in non
diabetic rats (FIG. 5).

At the beginning of treatm ent in the young hybrid rats (6 weeks old), there was
no significant difference in blood glucose levels between any of the rat groups.
Diabetic rats did not develop significantly elevated plasma glucose levels until
12 weeks of age. As the rats developed hyperglycemia, it was evident that both
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FIG. 4. Time course of oral pioglltazone effect on fasted plasma glucose levels
in young ZDF diabetic rats and non-diabetic littermates. Data represent the means
± SEM. Error bars smaller than symbols are not shown. #, significantly different
from diabetic untreated from this point through 13 weeks. *, significantly different
from control untreated from this point through 13 weeks.
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5 Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on fasting plasma glucose levels in older ZDF diabetic rats and non
diabetic littermates. Data represent the means ± SEM. Error bars sm aller than
sym bols are not shown. #, significantly different from diabetic untreated from
this point through week 2 0 . *, significantly different from control untreated from
this point through week 2 0 .
F IG .
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FIG 6. Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on fasted plasma glucose levels in young hybrid ZDF/SHHF diabetic
rats and non-diabetic littermates. Data represent the means ± SEM. Error
bars sm aller than symbols are not shown. #, significantly different from
diabetic untreated. *, significantly different from control untreated.
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the pioglltazone and vanadyl treatm ent groups had significantly low er plasma
than the untreated diabetic rat group (FIG. 6A,B).

Hydralazine treatm ent was

w ithout effect in the diabetic or non-diabetic groups (FIG. 6C).

Pioglltazone,

vanadyl or hydralazine had no effect on the non-diabetic rats.

3.3

Plasma Triglycerides

At seven weeks of age, young ZDF diabetic rats already had significantly higher
plasma triglyceride levels ( - 7 times) than the non-diabetic littermates. Within 2
weeks, pioglltazone normalized the elevated triglyceride levels and maintained
these levels throughout the study (FIG. 7).

Thirteen w eek old, older ZDF diabetic rats had significantly elevated plasm a
triglyceride levels (~5 tim es) com pared to non-diabetic rats.

P ioglltazone

significantly decreased triglyceride levels from DU levels at weeks 3 and 7 of
treatm ent (FIG. 8A).

Vanadyl had no effect on plasma triglyceride levels in

diabetic rats (FIG. 8B).

Hydralazine treatm ent significantly decreased plasma

triglycerides in the diabetic rats at weeks 1, 3 and 7 of treatm ent (FIG. 8C).
C ontrol rats, treated with either pioglltazone, vanadyl or hydralazine, had
significantly lower triglyceride levels compared to CU after 3 weeks of treatment.

Six w eek old, young hybrid diabetic rats were not hypertriglyceridem ic.

By 8

weeks of age, diabetic rats had significantly elevated triglyceride levels which
progressively increased through 12 weeks of age at which time they plateaued.
P ioglltazone sig n ifica n tly reduced, but did not norm alize, th e se elevated
triglyceride levels and had no effect in the non-diabetic rats (FIG. 9A). Vanadyl
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FIG. 7. Tim e course of oral pioglltazone effect on fasted plasma triglyceride
levels in young ZDFdiabetic rats and non-diabetic littermates. Data represent
m eans ± SEM. Error bars sm aller than symbols are not shown. #, significantly
different from diabetic untreated from this point through 13 weeks.
*, significantly different from control untreated from this point through 13 weeks.
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FIG. 8 , Time course of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
effects on fasted plasma triglyceride levels in older ZDF diabetic rats and
non-diabetic littermates. Data represent means ± SEM. Error bars smaller
than symbols are not shown. #, significantly different from diabetic untreated.
*, significantly different from control untreated.
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FIG. 9. Time course of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine
effects on fasted plasma triglyceride levels in young hybrid ZDF/SHHF diabetic
rats and non-diabetic littermates. Data represent means ± SEM. Error bars
sm aller than symbols are not shown. #, significantly different than diabetic
untreated from this point through week 14. *, significantly different from control
untreated from this point through week 14.
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caused a significant reduction in triglyceride levels compared to DU at w eek 14
when vanadyl dosing was at its highest (FIG. 9B). Hydralazine had no effect on
triglycerides in diabetic or non-diabetic hybrid rats (FIG. 9C).

3.4

Plasma Cholesterol

Fasted plasm a values following 6 weeks of vehicle treatm ent in young ZDF
diabetic rats (7-13 weeks of age) indicated that DU rats had significantly higher
glucose, triglyceride, total and HDL cholesterol and free fatty acids than did
non-diabetic rats. Pioglitazone, administered for 6 weeks, significantly reduced
the hyperglycem ia, hypertriglyceridem ia and hypercholesterolem ia but had no
effect on HDL or free fatty acid levels in the DU rats . Pioglitazone given to non
diabetic rats had no effect on any of the mentioned plasma parameters (Table
1).

O lder ZDF diabetic rats (13-20 weeks of age) exhibited significantly elevated
fasted glucose, triglycerides, total cholesterol, free fatty acids and hemoglobin
A1c than did control rats after 7 weeks of treatment. There was no difference
between CU and DU with respect to HDL cholesterol.
s ig n ific a n tly

reduced

Insulin values were

in d ia b e tic groups com pared to co n tro l groups.

Pioglitazone and hydralazine treatm ent groups had plasma triglyceride levels
that were intermediate between those of DU and CU rats. Vanadyl significantly
reduced plasm a glucose in diabetic rats.

O nly pioglitazone sign ifican tly

decreased free fatty acid levels relative to CU and DU rats (Table 2).
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TABLE 1. Effect of oral pioglitazone treatment on plasma glucose, triglycerides, total and HDL
cholesterol, free fatty acids and insulin after 6 weeks of treatment in young ZDF diabetic rats and non
diabetic littermates.
PLASMA
PARAMETER
Glucose
(mg/dl)
Triglycerides
(mg/dl)
Total Cholesterol
(mg/dl)
HDL Cholesterol
(mg/dl)
FFA
(pmol/l)
Insulin
(ng/ml)
HbAtc
(percent)

DU
(n=12)

DP
(n=12)

CU
(n=11)

CP
(n=12)

285.6 ± 30.0 *

109.8 ±8.1 #

92.4 ± 4.0 #

96.8 ± 6.2 #

1

(/)
(/>
CD

Q.

"O
CD

613.8 ±54.1 *

148.7 ± 1 6 . 2 #

95.9 ± 14.6 #

67.0 ± 5.0 #

2
Q.
C

17 4.0+14.0 *

135.0 ± 1 1 . 0 * #

8 2 . 0 ± 1 1 .0 #

78.0 ± 9.0 #

147.0 ± 2 9 . 0 *

121.0 ± 2 1 . 0 *

64.0 ± 7.0 #

64.0 ± 1 2 . 0 #

127.0 ± 1 0 . 6 *

123.4 ± 1 5 . 2 *

39.0 ± 8 . 2 #

49.2 ± 5.8 #

16.6 ± 2 . 6

29.5 ± 3.0 *

12.4 ± 2.4

9.6 ± 2.4

—

—
"

NOTE; A dash indicates that this parameter was not measured. Results represent means ± SEM; n,
number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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TABLE 2. Effect of oral pioglltazone, vanadyl and hydralazine treatment on plasma glucose, triglycerides, total
and HDL cholesterol, free fatty acids and insulin after 7 weeks of treatment in older ZDF diabetic rats and non
diabetic littermates.
PLASMA
PARAMETER
Glucose
(mg/dl)
Triglycerides
(m^dl)
Total
Cholesterol
(mg/dl)
HDL
Cholesterol
(mg/dl)
FFA
(timol/l)
Insulin
(ng/ml)
HbAtc
(percent)

DU
(n=5)
350.2 *
±5.9

DP
(n=5)
330.8 *
±12.5

DV
(n=5)
229.4 #*
± 17.0

DH
(n=4)
299.5 *
±9.3

CU
(n=5)
108.6 #
±7.1

CP
(n=5)
94.2#
±6.2

CH
(n=4)

CV
(n=5)
92.6 #
± 1.1

90.0#
± 6 .6

95.8#
±22.2

68.3#
± 17.5

694.2 *
± 117.3

481.6 r
±49.5

153.6
±13.4*

147.4 ± 8.4* 132.4 ±6.9*

142.8 ± 8.2* 56.6 ±2.65# 53.4 ± 1 .2 #

68.2 ± 4.0 #

51.5 ± 3 .3 #

83.6 ± 37.4

55.1 ± 19.5

71.1 ±14.9

95.5 ± 14.7

39.2 ± 2.2

36.3 ± 1 .4

49.0 ± 3.5

38.5 ± 1 .6

292.8 *
±25.1

247.9 *
±15.4

245.3 *
±40.9

300.4 *
±28.9

171.5 #
±3.6

142.8 #*
±9.7

173.68 #
±6.4

195.4 #
±40.8

5.9 ±1.9 *

3.2 ±0.4 *

6.8 ±1.0 *

5.0 ±0.6 *

22.6 ± 7.4 #

14.1 ± 2 .8 #

6.3 ± 1 .4 #

17.7 ± 4 .5 #

8.7 ±0.4 *

9.5 ±0.4 *

0.2 ±0.4 *

9.6 ±0.6 *

5.7 ± 0 .4 #

5.8 ± 0 .4 #

6.1 ± 0 .7 #

6.6 ± 1 .3 #

565.0 *
±71.5

471.8 #*
±34.8

158.2 #
±21.9

106.8 #
±7.2
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NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.

o
c
g

'((//)>
CD

Q.

"O
8
3
"O
2
Q.

Q1
CD

U)

TABLE 3. Effect of oral pioglitazone, vanadyl and tiydralazine treatment on plasma glucose, triglycerides, total
and HDL cholesterol, free fatty acids and insulin after 8 \weeks of treatment in young hybrid ZDF/SHHF diabetic
rats and non-diabetic littermates.

fPLASMA
PARAMETER
1Glucose
(mg/dl)
Triglycerides
(mg/dl)
Total
Cholesterol
(mq/dl)
HDL
Cholesterol
(mg/dl)
FFA
(umol/l)
Insulin
(ng/ml)
HbAlc
(percent)

(/)
(/>

DU
(n=7)

DP
(n=7)

DV
_Ln=4)

DH
(n=4)

CU
(n=7)

CP
(n ^

CH
(n=4)

c v

(n=4)

CD

Q.

304.8
±34.9*

195.1
±10.5#

239.4
±15.5#*

365.3
±45.0*

170.3
± 8.0 #

158.6
±7.0#

156.2
±17.6#

170.4
±5.4#

"O

1267.2
± 142.2*

328.9
± 35.0#*

755.9
± 243.2#*

1197.6
± 235.8*

128.1
± 10.8#

77.1
±4.5#

70.2
± 13.3#

62.2
±8.3#

2
Q.

189.1
± 11.4*

92.2
±6.5#

149.2
± 24.4*

102.8
± 17.0#*

79.6
± 10.0#

54.7
±3.7#

59.0
±6.3#

54.7
±6.1#

67.6 + 1.6*

61.6 ±3.3*

72.0 ± 4.2*

78.5 ±1.4*#

48.1 ± 2.0#

39.7 ±1.6#

44.7 ± 6.7#

41.2 ±2.1#

CD

C

g
"G
3
"O
2
Q.
2
-c

259 ± 20

253 ± 26

262 ± 31

276 ± 10

247± 11

186 ±1 9

230 ± 62

243 ± 22

33.8 ± 5.2*

13.1 ± 1.6#

26.6 ± 3.5*

29.4 ± 8.7*

7.2 ±1.1#

5.3 ± 0.4#

5.7 ± 2.1#

7.1 ±1.5#

6.39
±0.4*

5.20 ±
0.38#

6.33
± 0.47*

6.67
± 0.59*

4.22
± 0.34#

4.66
± 0.40#

5.06
± 0.39#

4.68
± 0.82#

È
8
CD

O
C

g

NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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Young hybrid ZDF/SHHF diabetic rats (6-14 weeks of age) showed significantly
elevated fasted plasm a glucose, triglycerides, total and HDL cholestérols,
insulin and hem oglobin A le com pared to CU rats follow ing 8 w eeks of
treatm ent (Table 3). Pioglitazone normalized plasma glucose, total cholesterol,
insulin and hem oglobin A le in the DP group and significantly decreased
triglycerides relative to DU. Vanadyl significantly reduced plasma glucose and
triglyceride levels whereas hydralazine significantly reduced total and elevated
HDL cholesterol levels. There was no effect by any drug on control rats. There
was no difference between any groups with respect to free fatty acid levels.

3.5

Cardiac Performance

C ardiac perform ance w as m easured by three param eters:

left ventricular

developed pressure (LVDP), rate of force developm ent by the left ventricle
(+dP/dt), and rate of relaxation by the left ventricle (-dP/dt).

LVDP was not

affected by diabetes alone (DU) at any of the preload pressures from 7.5 to 22.5
cm H2O in young ZDF diabetic rats (FIG. 10), in older ZDF diabetic rats (FIG. 11)
or In young hybrid ZDF/SHHF diabetic rats (FIG. 12).

Pioglitazone treatm ent

caused a significantly reduced function in young ZDF diabetic rats at the two
lowest preloads (7.5 and 10 cm H2 O) compared to CU rats.

In young hybrid

ZDF/SHHF rats, pioglitazone caused control rats to have significantly improved
function at the three highest preloads (17.5, 20 and 22.5 cm H2O) compared to
CU (FIG. 12A).

Vanadyl and hydralazine did not influence LVDP in either

diabetic or non-diabetic rats in either older ZDF (FIG. 11 B,C) or young hybrid
ZDF/SHHF rats (FIG. 12B,C).
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Rate of force development (+dP/dt) was also not affected by diabetes in young,
old or hybrid ZDF diabetic rats compared to non-diabetic rats (FIG. 13, 14, 15).
As with LVDP, pioglitazone treatm ent significantly reduced diabetic heart
function, at the two lowest preloads tested (7.5 and 10 cm H 20 ) in young ZDF
diabetic rats (DP; FIG. 13), but not in the older ZDF diabetic or young hybrid
ZD F/SHHF diabetic rats compared to CU (FIG. 13). Young ZDF diabetic rats
have im paired function com pared to CU rats, but this trend was not seen in
older ZDF diabetic rats or young hybrid ZDF/SHHF diabetic rats. Vanadyl and
hydralazine had no significant effect on rate of force developm ent in either
diabetic or control young, old or hybrid ZDF rats (FIG. 14B.C; 15B.C).

Rate of ventricular relaxation (-dP/dt) showed sim ilar responses to +dP/dt and
LVDP in that there was no significant effect of untreated diabetes on this
cardiovascular param eter in old, young or hybrid ZDF diabetic rats relative to
non-diabetic litterm ates.

A trend seem s apparent, suggesting that diabetic

hearts have im paired fu nctio n in young ZD F d ia b etic rats (FIG .

16).

Pioglitazone significantly Impaired diabetic heart function, but only at the two
lowest preloads tested (7.5 and 10 cm H 20) in the young ZDF diabetic rats (FIG.
16).

Hydralazine caused diabetic rat hearts to relaxed significantly slow er (-

dP/dt) than control hearts at the three highest pressures (17.5, 20 and 22.5 cm
H 2 0 ) and caused hearts of the CH rats to have significantly increased function
at the same three high pressures compared CU or DU (FIG. 17C). Pioglitazone
and vanadyl had no effect on -dP/dt in diabetic or non-diabetic older ZDF and
young hybrid ZD F/SH H F rats (FIG. 17A,B; 18A,B).

Hydralazine also affected

-dP/dt in young hybrid ZDF/SHHF diabetic hearts (FIG. 18C). Diabetic hearts
exposed to hydralazine had significantly elevated rates of relaxation com pared
to CU at the 4 highest preloads (15, 17.5, 20 and 22.5 cm H 20).
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FI G . 10. Influence of oral pioglitazone on left ventricular developed pressure
(LVDP) in isolated working hearts of young ZDF diabetic rats and non-diabetic
littermates. Results illustrate the LVDP as left atrial filling pressures changed at
2.5 cm H 2 0 intervals from 7.5 to 22.5 cm. Data represent mean ± SEM.
*, significantly different than control untreated.
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FIG. 11. Influence of oral (A) pioglitazone, (B) vanadyl and (0) hydralazine on
left ventricular developed pressure (LVDP) in isolated working hearts of older
ZDF diabetic rats and non-diabetic littermates. Results illustrate the LVDP as left
atrial filling pressures changed at 2.5 cm H 2 0 Intervals from 7.5 to 22.5 cm.
Data represent m eans + SEM. *, significantly different from control untreated.
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FIG. 12. Influence of oral (A) pioglltazone, (B) vanadyl and (C) hydralazine
on left ventricular developed pressure (LVDP) in isolated working hearts of
young hybrid ZDF/SHHF diabetic rats and non-diabetic littermates. Results
illustrate LVDP as left atrial filling pressures changed at 2.5 cm H 2 0 intervals
from 7.5 to 22.5 cm. Data represent mean + SEM. *, significantly different
than control untreated.
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FIG. 13 Influence of oral pioglitazone on rate of force development (+dP/dt)
In isolated working hearts of young ZDF diabetic rats and non-diabetic litter
mates. Results illustrate +dP/dt in the left ventricle as left atrial filling
pressures changed at 2.5 cm H 2 0 intervals from 7.5 to 22.5 cm. Data
represent mean ± SEM. *, significantly different from control untreated.
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FIG. 14. Influence of oral (A) pioglitazone, (B) vanadyl and (G) hydralazine
on rate of force developm ent (+dP/dt) In isolated working hearts of older ZDF
diabetic rats and non-diabetic littermates. Results illustrate the +dP/dt In the
left ventricle as left atrial filling pressures changed at 2.5 cm H 2 0 intervals
from 7.5 to 22.5 cm. Data represent mean ± SEM.
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FIG. 15. Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine
on rate of force developm ent (+dP/dt) in isolated working hearts in young
hybrid ZD F/SHHF diabetic rats and non-diabetic littermates. Results illustrate
the +dP/dt in the left ventricle as left atrial filling pressures changed at 2.5 cm
H 2 0 intervals from 7.5 to 22.5 cm. Data represent mean ± SEM.
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FIG. 16. Influence of pioglitazone on rate of relaxation (-dP/dt) In
Isolated working hearts of young ZDF diabetic rats and non-diabetic
littermates. Results illustrate the -dP/dt of the left ventricle as left
atrial filling pressures changed at 2.5 cm H 2 0 Intervals from 7.5 to
22.5 cm. Data represent mean ± SEM. *, significantly different than
control untreated.
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FIG. 17. Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine
on rate of relaxation (-dP/dt) in isolated working hearts in older ZDF diabetic
rats and non-diabetic littermates. Results illustrate the -dP/dt of the left
ventricle as left atrial pressures changed at 2.5 cm H 2 0 intervals from
7.5 to 22.5 cm. Data represent mean ± SEM. #, significantly different
from diabetic untreated. *, significantly different from control untreated.
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FIG. 18 Influence of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine
on rate of relaxation (-dP/dt) in isolated working hearts of young hybrid
ZDF/SHHF diabetic rats and non-diabetic littermates. Results illustrate the
-dP/dt of the left ventricle as left atrial filling pressures changed at 2.5 cm
H 2 0 intervals from 7.5 to 22.5 cm. Data represent mean ± SEM.
*, significantly different from control untreated.
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3.6

Vascular Reactivity

Vascular reactivity was measured by determ ining the ability of aortic rings to
contract after incremental doses of norepinephrine (NE).

Data were compiled

as dose response cun/es. In older ZDF diabetic rats, aortic sensitivity to NE was
s ig n ific a n tly increased com pared to untreated n on -d iab e tic litte rm a te s.
Pioglitazone significantly attenuated the aortic sensitivity of DU rats, but does
not norm alize it to CU levels. Pioglitazone had no effect on responsiveness in
non-diabetic rats (FIG. 19A). Vanadyl lowered NE responsiveness similarly, but
more potently and com pletely than pioglitazone relative to aortas of DU rats.
Vanadyl w as without effect on non-diabetic rats (FIG. 19B).

Hydralazine not

only failed to reduce aortic sensitivity to NE, but actually increased sensitivity
above that seen in tissues from untreated diabetic rats.

Regardless of diabetic

status or drug treatm ent, vascular reactivity was not changed in young hybrid
ZDF/SHHF rats (FIG. 20A,B,C).

The m axim al response to NE was significantly elevated in older ZDF diabetic
rats compared to CU rats. Pioglitazone and vanadyl decreased NE sensitivity in
diabetic rat aortas.

Hydralazine, on the other hand, significantly increased

sensitivity in non-diabetic rats with no effect relative to DU (Table 4),

The

m axim al response to NE in young hybrid ZD F/SHHF diabetic rats was not
d iffere nt than th a t of non-diabetic rats, nor did piogitazone, vanadyl or
hydralazine have any sigificant effect on this parameter (Table 5).

The maximal response to 40 mM KOI was also significantly higher in older ZDF
diabetic rats com pared to CU rats.

Pioglitazone and vanadyl significantly

reduced these levels in diabetic rats while vanadyl and hydralazine significantly
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FIG. 19 Effect of oral (A) pioglitazone, (B) vanadyl and (G) hydralazine
on norepinephrine dose response curves in isolated aorta of older ZDF
diabetic rats and non-diabetic littermates. Data represent mean ± SEM.
#, significantly different from diabetic untreated from that point throug
the rest of the curve. ", significantly different from control untreated
from that point through the rest of the curve.
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FIG. 20 Effect of oral (A) pioglitazone, (B) vanadyl and (C) hydralazine
on norepinephrine dose response curves in Isolated aorta of young
hybrid ZDF/SHHF diabetic rats and non-diabetic littermates. Data
represent mean ± SEM.
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TABLE 4. Effect of oral pioglitazone, vanadyl and fiydralazine on the maximal response to 40 mM KCI and
norepinephrine (NE) after 7 weeks of treatment in older ZDF diabetic rats and non-diabetic littermates.

"O
CD

40 mM KCI
(grams of
tension)
MAX. NE
RESPONSE
(grams of
tension)

DU (n=5)

DP (n=5)

1.60 ± 0 .1 2 *

1.06 ±0.05*# 1.08 ±0.12*# 1.30 ± 0 .0 6 *

DV (n=5)

DH (n=4)

CU (n=5)

CP (n=5)

CV (n=5)

CM (n=4)

2
Q.
C

0.63 ± 0.09 # 0.68 ± 0 .1 0 #

1.10 ±0.12*# 1.08 ± 0 .2 5 #

g
"G
3

"O
2.68 + 0.05*

1.66 +0.04*# 1.24 ± 0 .1 0 # 2.60 ± 0.12 *

1.03 ± 0 .1 3 #

1.06 ± 0 .0 7 #

1.30 ± 0 .0 9 #

1.95 ±0.06*#

2
Q.
2

■3c

u_

0
I
£
g
È
8
c

NOTE: Data represent means ± SEM; n, number of animals. Numbers represent fasted values.
#Significantly different from diabetic untreated.
‘ Significantly different from control untreated.
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TABLE 5. Effect of oral pioglitazone, vanadyl and fiydralazine on ttie maximal response to 40 mM KCI and
norepinepfirine (NE) after 8 weeks of treatment in young fiybrid ZDF/SHHF diabetic rats and non-diabetic
littermates.

DU (n=7)
40 mM KOI
(grams of
tension)
MAX. NE
RESPONSE
(grams of
tension)

DP (n=7)

DV (n=4)

DH (n=4)

CU (n=7)

CP (n=7)

CV (n=4)

CH (n=4)

0.44 ± 0.09

0.44 ± 0.07

0.40 ± 0.06

0.43 ± 0.06

0.61 ± 0.18

0.46 ± 0.06

0.30 ± 0.10

0.50 ± 0.06

(/)
(/>
CD

0.44 ± 0.08

0.40 ± 0.08

0.38 ± 0.05

0.78 + 0.25

0.39 ±0.10

0.33 + 0.13

0.53 ±0.10

Q.

"O
0.50 ±0.11

CD

2
Q.
C

g
"G
3

"O

NOTE: Data represent means ± SEM; n, number of animals. Numbers represent fasted values.
#Significantfy different from diabetic untreated.
•Significantly different from control untreated.
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Increased the response in non-diabetic littermates (Table 4).

In young hybrid

ZD F/SHHF rats there was no significant difference with respect to the response
to 40 mM KCI in any treatment group (TableS).

3.7

C ardiovascular Parameters

Additional cardiovascular parameters measured included systolic and diastolic
blood pressure, m ean a rte ria l blood pressure, cardiac ch ole stero l and
triglycerides, heart w eight and heart weight to body weight ratios.

Systolic,

diastolic and mean arterial blood pressures were not measured in young ZDF
diabetic and non-diabetic rats due to lack of necessary equipment.

Cardiac

cholesterol did not differ between diabetic and non-diabetic rats and no effect
was observed with pioglitazone treatment. There was a significant difference
between diabetic and non-diabetic levels of cardiac triglycerides. Pioglitazone
treatm ent lowered cardiac triglycerides in both diabetic and non-diabetic rats.
P io glita zon e s ig n ific a n tly increased heart sizes in diabetic rats and in
conjunction with significantly elevated body weights resulted in significantly
lower heart w eight to body w eight ratios com pared to untreated and non
diabetic rats (Table 6).

Hydralazine, but not pioglitazone or vanadyl, significantly decreased systolic,
diastolic and m ean arterial blood pressures in both diabetic and non-diabetic
older ZDF rats. Cardiac cholesterol in diabetic rats was significantly decreased
compared to non-diabetic rats. Hydralazine, but not pioglitazone and vanadyl,
significantly decreased cardiac cholesterol in control rats with no effect seen in
diabetic rats. Cardiac triglycerides are significantly higher in diabetic compared
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to non-diabetic rats.

Vanadyl therapy significantly reduced elevated cardiac

triglyceride levels in DU rats. Diabetic heart weight and body weights were not
sig n ific a n tly d iffere nt from heart w eights in non-diabetic rats.

V anadyl

significantly lowered body weights in both diabetic and non-diabetic rats and
significantly lowered heart weights in diabetic rats. None of the drug treatments
modified heart weight to body weight ratios (Table 7).

Although a relative trend appears for hydralazine to decrease systolic, diastolic
and mean arterial blood pressures in young hybrid ZDF/SHHF rats compared to
untreated diabetic and non-diabetic young hybrid ZDF/SHHF rats, significant
changes were not observed.

Pioglitazone did decrease systolic, diastolic and

mean arterial blood pressures in diabetic rats compared to CU rats.

Cardiac

cholesterol and triglyceride levels were not altered by pioglitazone, vanadyl or
hydralazine in either diabetic or non-diabetic rats.

Pioglitazone treatm ent

caused significantly increased heart weights in diabetic rats compared to CU
and DU.

Diabetic rats had significantly elevated body weights com pared to

control rats. Pioglitazone treatm ent significantly increased the body weights of
diabetic rats whereas vanadyl significantly decreased body weights compared
to DU rats. Vanadyl and hydralazine treatment also significantly reduced body
w eights in non-diabetic rats com pared to CU and DU rats; however, this
phenom enon occurred from the initiation of the study and was probably not
reflective of drug effect.

Heart weight to body weight ratios were significantly

increased by hydralazine in control rats but not diabetic rats.
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TABLE 6. Effect of oral pioglitazone treatment on systolic, diastolic and mean arterial pressures, cardiac
cholesterol and triglycerides, heart weight, body weight and heart weight to body weight ratio after 6 weeks of
treatment in young ZDF diatietic rats and non-diabetic littermates.

1CARDIAC
1 PARAMETER
Systolic/Diastolic
(mmHg)
Mean Arterial
Pressure (mmHg)
Cardiac
Cholesterol
(nmol/mg protein)
Cardiac
Triglycerides
(nmol/mg protein)
Heart Weight
(grams)
Body Weight
(grams)
Heart: Body
Weight Ratio
(X10-3)

DU
(n=12)

DP
(n=12)

CU
(n=11)

(/)
(/>

CP
(n=12)

CD

Q.

*“
—

237.5 ± 26.4

""
—

217.6126.1

226.0132.1

—

"O
CD

183.0122.3

2

Q.
C

280.0 ± 35.5 *

168.012 5.9#

142.0 1 30.2#

81.0112.8 #*

1.91210.078

2.22310.087 #*

1.75510.053

1.931 10.068

g
"G
3
"O
2
Q.
2

■c
CD

439.9 ± 7.4 *

633.4110.7*#

363.4 1 6.8#

37 9 .8 1 6 .3 #

4.3410.15

3.5110.11 * #

4.8 510.20

5.0 91 0.18

C

I
£
g
È
8

g

CD

O
C

g

'((//)>
NOTE; A dash indicates that this parameter was not measured. Results represent means ± SEM; n, number of
animals. Numbers represent fasted values.
# Significantly different from diabetic untreated.
* Significantly different from control untreated.
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TABLE 7. Effect of oral pioglitazone, vanadyl and hydralazine treatment on systolic, diastolic and mean arterial
blood pressures, cardiac cholesterol and triglycerides, heart weight, body weight and heart weight to body weight
ratio after 7 weeks of treatment in older ZDF diabetic rats and non-diabetic littermates.

CARDIAC
PARAMETER
Systolic/
Diastolic
(mmHg)
Mean Arterial
Blood
Pressure
(mmHg)
Cardiac
Cholesterol

DU
(n=5)
143/105

DP
(n=5)
140/116

DV
(n=5)
140/102

DH
(n=4)
104#*/78 * '

CU
(n=5)
136/111

CP
(n=5)
145/111

CV
(n=5)
142/105

CM
(n=4)

CD

Q.

1 0 1**/80#'
"O
CD

118±8

124 ± 8

116±11

91 ± 7 * '

120 ± 1 0

126 ± 6

1 1 7± 7

87±8#'

2

Q.
C

g
"G
3
"O
15.26 ±2.8

16.08 ± 3.6

20.78 ±1.0#

16.20 ± 1.6

18.68 ± 1.9

7.55 ± 0.6#*

2
Q.
2

16.08 ±1.6* 18.96 ±2.0*

9.10 ±1.1 #

24.1±3.0#*

8.17 ±0.4#

5.81 ± 0.7#

4.70 ± 0.6#

7.54 ± 0.3#

■c

1.7 ±0.1

1.3 ±0.1#

1.7 ±0 .2

1.7 ±0.1

1.4 ±0.1

13.80 ±1.9*

18.07 ±1 .5

(nmoVmg protein)

Cardiac
Triglycerides

(/)
(/>

(nmol/mg protein)

Heart Weight
(grams)
Body Weight
(grams)
Heart:Body
Weight ratio

CD

1.8 ±0.2

1.6 ±0.1

1.6 ±0.2

C

450.0
± 10.8

472.8
±9.8

347.6
± 14.7#*

432.8
±8.0

442.6
± 17.1

495.6
± 13.8

354.0
±9.2#*

432.8
±20.5

I
£
g
È

3.83 ± 0.04

3.88 ± 0.19

3.84 ± 0.08

3.73 ±0.12

3.83 ±0.11

3.51 ± 0.13

4.00 ±0.11

3.74 ± 0.22

g

(X 1 0 -3 )

8
CD

O
C

g

'((//)>
CD

Q.

NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted plasma values.
#Significantly different from diabetic untreated.
‘ Significantly different from control untreated.
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TABLE 8. Effect of oral pioglitazone, vanadyl and fiydralazine treatment on systolic, diastolic and mean arterial
blood pressure, cardiac cholesterol and triglycerides, heart weight, body weight and heart weight to body weight
ratio after 8 weeks of treatment in young hybrid ZDF/SHHF diabetic rats and non-diabetic littermates.
CARDIAC
PARAMETER
Systolic/
Diastolic
(mmHg)
Mean Arterial
Blood
Pressure
(mmHg)
Cardiac
Cholesterol

DU
(n=7)
130/88

DP
(n=7)
117*/78*

DV
(n=4)
140/94

DH
(n=4)
118/79

CU
(n=7)
154/106

CP
(n=7)
1 4 0/9 3

CH
(n=4)

CV
(n=4)
149 /1 0 4

12 5/7 7

CD

Q.

"O
CD

103 ± 6

91+4*

109 ± 8

92±6

123 ± 4

109 ± 7

119±12

93 ± 1 7

2

Q.
C

g
"G
3
"O
10.81 ± 1.3

12.71 ± 1.5

12.30 ± 2.1

13.75 ±2 .7

9.72 ±1.2

12.03 ± 2.0

13.24 ± 3.7

16.72 ± 2.0

2
Q.
2

8.49 ± 1.4

8.68 ±1.6

8.53 ±1.3

9.05 ±1.6

4.67 ± 0.3

5.70 ± 0.7

4.92 ± 1 .4

9.33 ± 1.75

■c

1.818
± 0.034

2.027
+ 0.049 #*

1.738
± 0.058

1.737
± 0.013

1.760
± 0.027

1.883
± 0.039

1.534
±0.13

1.741
± 0.063

571+6*

708 + 8#*

541 ± 7 # *

548 ± 16*

446 ± 6 #

469±10#

360 ± 14 #*

385 ± 1 4 # *

3.186
+ 0.067 *

2.866
± 0.074 *

3.209
± 0.074 *

3.174
± 0.068 *

3.952
± 0.082 #

4.027
± 0.099 #

4.248
± 0.240 #

4.542
± 0.204 #*

(nmoVmg protein)

Cardiac
Triglycerides

(/)
(/>

(nmol/mg protein)

Heart Weight
(grams)
Body Weight
(grams)
HeartiBody
Weight ratio

CD

C

I
£
g
È
8

g
O
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C

g

'((//)>
NOTE: Results represent means ± SEM; n, number of animals. Numbers represent fasted values.
#Significantly different from diabetic untreated.
•Significantly different from control untreated.
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DISCUSSIO N

Increased body weight is apparently an important factor in insulin resistance
and hyperlipidem ia in NIDDM.

This is particularly true In obese NIDDM

patients, in whom It has been shown that significant weight loss through diet
and exercise can alleviate insulin resistance and possibly eliminate the need to
take oral hypoglycemic agents. If adequate control can not be attained with diet
and exercise, drug therapy is necessary.

Z u cke r D iabetic F atty (ZDF) rats are hyperinsuliném ie, hyperglycem ic,
hypertriglyceridem ic and hypercholesterolemic and simulate human NIDDM. At
an older age, these ZDF rats develop IDDM, become hypoinsulinem ic and
remain hyperglycemic, hypertriglyceridemic and hyper-cholesterolemic. Hybrid
ZD F/SH H F rats maintain the same characteristics of the young ZDF rats, but
have the added potential of developing hypertension and/or congestive heart
failure.

In all 3 groups of rats, diabetic fatty rats had elevated body weight

com pared to control rats at some point.

In the young and older ZDF, this

Increased body weight occurred from the initiation of the study (7 weeks and 13
weeks, respectively); however, the significantly increased body weight of young
hybrid ZDF/SHHF diabetic rats occurred only after the rats reached 9 weeks of
age.

Pioglitazone, a thiazolidinedione, caused a significant increase in body weights
in the young ZDF diabetic rats and young hybrid ZDF-SHHF diabetic rats.
There was not a significant body weight increase in young, old or hybrid non
diabetic rats treated with pioglitazone.

In the older non-diabetic ZDF rats,

pioglitazone appeared to cause an increase in body weight, but this trend was
76
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not significant. By the end of the study in older ZDF rats (20 weeks of age) all
diabetic and non-diabetic groups, except the vanadyl treated animals, had body
w eights that were not significantly different from each other. This body weight
gain is consistent with results seen in KKAV mice (Hofmann et al., 1991) and
W istar diabetic fatty rats (Sugiyama et al., 1990), even though their pioglitazone
treatm ent lasted for a much shorter period of time. Sugiyama (1990) suggests
that the increased body weight is attributed to increased food consum ption in
W istar fatty rats (a rat model of NIDDM) treated with pioglitazone. It has also
been shown that the effects of pioglitazone occur only in hyperinsulinémie rats
and not normal or hypoinsulinem ic states (Ikeda, 1990; Hofmann et al., 1991).
T his agrees w ith o u r study w here body w eight gains o nly e xisted in
hyperinsuliném ie young ZDF and young hybrid ZD F/SH H F rats, but not in
hypoinsulinem ic older ZDF rats. Food consumption was not directly measured
In our experim ents, but increased consumption could be observed on a daily
basis by visual exam ination.

Increased food consum ption has also been

reported as a result of insulin injection. It would seem that an increase in body
weight would not be beneficial to NIDDM diabetic patients, the m ajority of whom
are already obese; how ever, these and other studies conclude that there
appears to be no detrim ental effect on plasm a com ponents caused by
pioglitazone.

Vanadyl sulfate treatm ent in older ZDF diabetic and non-diabetic litterm ates
caused a significant reduction in body weights coincidental with a decrease in
plasma glucose. This effect was also seen in the young hybrid ZDF/SHHF rats,
but only after 8 weeks of treatm ent. Perhaps this is because the rats had not
been at an adequate concentration for a sufficinet period of time since the rats
were slow ly brought up to a concentration known to decrease plasm a glucose
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study and at that point there was a significant decrease in plasma glucose in the
diabetic rats treated with vanadyl.

It has been suggested that the antidiabetic

effects of vanadyl are mediated entirely through its appetite suppression caused
w eight loss (Malabu, U.H. et al., 1994). There are many reports, using pair fed
anim als, which contradict Malabo's theory.

In these experiments, obese fa/fa

rats w ere treated with food restrictions sim ilar to the reduced consum ption
observed in vanadyl treated rats. These rats were compared to vanadyl treated
obese fa/fa rats. It was determined that oral vanadate but not food restrictions
decreased muscle insulin resistance in these obese rats (Brichard, S.M., 1992).

W ith optim al control of diabetes In humans and rats, plasma glucose levels
decrease and approach 100 mg/dl. Clinically, fasting plasma glucose greater
than 150 mg/dl is considered hyperglycemic. In old, young and hybrid diabetic
rat groups (DU), plasm a glucose levels were significantly elevated, albeit at
different ages.

The difference in ages of the animal models at the onset of

treatm ents (7 w eeks, young ZDF; 13 weeks, older ZDF; 6 w eeks, hybrid
ZD F/SH H F) resulted in tw o groups that were not hyperglycem ic (young, a;
hybrid, c) and one group that was hyperglycemic (older, b). In the young ZDF
diabetic rats, hyperglycem ia (286 ± 30 mg/dl) was established at 9 w eeks of
age; in young hybrid ZDF/SHHF rats, hyperglycemia (305 ± 35 mg/dl) became
evident at 12 weeks of age.

Regardless of treatment, non-diabetic rats did not

develop hyperglycem ia spontaneously nor did they become hypoglycemic after
pioglitazone, vanadyl or hydralazine treatment.

Pioglitazone adm inistration significantly reduced plasm a glucose levels in the
young ZDF diabetic and young hybrid ZDF/SHHF diabetic rats, but not in the
o ld e r rat group.

T his

is p ro b a b ly a ttrib u ta b le

to the fa c t th a t th e
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thiazolidinediones require some level of insulin to be effective; by the end of the
study the older rats had apparently converted from type II (hyperinsulinémie) to
typ e I (hypoinsulinem ic) diabetics.

This was indicated by the significant

decrease in insulin levels in diabetic rats with respect to non-diabetic rats. This
indicated a possible destruction of pancreatic p cells that originally tried to
overcom pensate for the elevated glucose levels in the diabetic rats.

One

suggested m echanism for the glucose lowering effect of pioglitazone is to
stim ulate expression of GLUT 4 glucose transporter mRNA.

These new

transporters subsequently translocate to membranes where they stim ulate the
rapid rem oval of glucose from the bloodstream into fat and muscle.

This

phenom enon has been observed in several m odels of insulin resistance in
adipose tissue and m uscle (Hofmann et al, 1991).

By increasing transporter

num ber and sta bilizin g m essage expression, stim ulation of storage and
m etabolism of glucose can be expected as well as increased insulin sensitivity
leading to decreased insulin resistance (Sandouk et at., 1993).

Also of interest was the observation that although rats were given a pioglitazone
dose 3 fold greater than those reported necessary to control plasma glucose, no
hypoglycem ia w as observed even when the rats w ere dosed and fasted
concurrently. This is a significant advantage over the sulfonylureas in treating
NIDDM. These com pounds are known to cause hypoglycemia, w hich can be
severe, as a side effect of treatment.

Hydralazine treatm ent had no effect on blood glucose levels in any of the rats.
Vanadyl sulfate, however, did significantly lower plasm a glucose in older ZDF
diabetic rats, but did not normalize plasma glucose, possibly because the dose
w as not given in adequate amounts for a sufficient period of time. Vanadyl at
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m axim um concentrations lowered the plasma glucose levels of young hybrid
ZD F diabetic rats once hyperglycem ia was established.

Vanadyl has been

know n to reduce plasm a glucose levels in ob/ob mice, a m odel of NIDDM
(Brichard et al., 1990) and in STZ-diabetic rats, a model of IDDM with low levels
of circulating insulin (Heyliger et al., 1985).

Vanadyl is known to improve Insulin sensitivity and reduce insulin resistance in
diabetic rats, consistent with our results from old and hybrid diabetic rats.
V anadyl's reported ability to increase the dim inished GLUT4 transporters in
diabetic rats (Strout et al., 1990; Paquet et al., 1990) may be responsible for
these effects.

Since elevated plasma insulin levels (hyperinsulinemia) are a good indicator of
NIDDM and insulin resistance and given that the overall mechanism of action of
p io g lita zo n e is to reduce insulin resistance, plasm a insulin levels w ere
determined.

If not corrected, hyperinsulinem ia in diabetic and/or obese states

can cause hepatic glucose production to increase and glucose utilization to
decrease despite the presence of insulin (Defronzo et al., 1982).

These

metabolic abnormalities worsen the diabetes and make control very difficult.

Young ZDF rats m aintained m oderately elevated insulin values regardless of
diabetic status.

These levels were somewhat greater than those seen in the

non-diabetic rats of hybrid origin (the other NIDDM group). O lder ZDF diabetic
rats had significantly lowered plasma insulin levels (sim ilar to IDDM) compared
to non-diabetic rats; w hereas, young hybrid ZD F/SH H F diabetic rats had
significantly elevated insulin levels compared to non-diabetic littermates (sim ilar
to NIDDM). Pioglitazone did not appear to reduce the hyperinsulinem ia seen in
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young ZD F diabetic rats.

It also did not have an effect on the already low

plasm a insulin levels of the older ZDF diabetic rats. Pioglitazone did, however,
significantly reduce plasma insulin levels in young hybrid ZDF/SHHF diabetic
rats.

T hese results are consistent with NIDDM models where pioglitazone

works only when insulin is present. This explains why the drug was ineffective
in the older rats that converted to IDDM with low insulin levels. By the end of the
treatm ent period, the control rats had also begun to make the conversion to type
II diabetes as evidenced by their significantly higher plasm a insulin levels
com pared to the diabetic rats.

A possible explanation for the failure of

pioglitazone to elim inate hyperinsulinem ia in the young ZDF diabetic rats (DU,
17 ± 3 ng/ml) m ight be that their insulin levels never reached the extrem ely
elevated levels seen in the young hybrid ZDF/SHHF diabetic rats (DU, 35 ± 5
ng/ml).

Unlike pioglitazone, which improves insulin sensitivity, vanadyl tends to mimic
insulin's actions.

Vanadyl sulfate m im ics the actions of insulin and thus is

effective in im proving glucose tolerance in NIDDM and IDDM m odels.

No

change in insulin levels were noted with vanadyl or hydralazine in diabetic or
non-diabetic rats of young, old or hybrid origin.

It has been suggested that the insulin resistance in W istar Fatty NIDDM rats may
be am eliorated by the activation of tyrosine kinase activity in insulin receptors
(Kobayashi et al., 1992).

However, in that study, it w as never established

w hether this was a secondary effect of metabolic improvement or a direct effect.
Tyrosine kinase is necessary for property functioning insulin receptors.
in su lin b in d s to the a

su bu nit, th e

re c e p to r's

autophosphorylation at its tyrosine residues.

p

s u b u n it

A fter

u n d e rg o e s

T his results in activation of
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tyro sin e kinase w hich phosphorylates substrates e ventually resu lting In
insulin's effects.

Insulin resistance has also been associated with elevated triglycerides and fatty
acids since fatty acids are preferentially m obilized from adipose tissues and
glucose disposal is inhibited (Kobayashi et al., 1992).

Elevated triglycerides

and cholesterol and decreased HDL cholesterol levels have been linked to
Increased incidence of coronary artery disease.

Thus it is very im portant for

diabetics and others with elevated lipids to norm alize th eir lipids.

This is

e sp e cia lly true fo r d ia b e tics w ho have a higher incidence of va scu la r
abnorm alities such as hypertension as a consequence of their disease.

Pioglitazone significantly lowers the elevated triglycerides observed in young,
older and hybrid diabetic rats after 6, 7 and 8 weeks of treatm ent respectively.
In the young ZDF diabetic rats, pioglitazone caused a complete normalization of
plasma triglyceride levels by two weeks of treatment. In older ZDF diabetic rats,
the effect was much more modest and plasma triglycerides were not completely
norm alized to control levels.

In fact, the effect was only seen after 3 and 7

weeks of treatment, but not at 5 weeks of treatment. This could be a result of the
conversion from type II to type I diabetes with its relative deficiency of insulin, a
situation known to interdict pioglitazone activity. Young hybrid diabetic rats did
not exhibit elevated triglycerides from the start of the experim ents as did the
young and older ZD F rats.

However, when the hybrid ZDF diabetic rats

developed hypertriglyceridem ia, the degree of hypertriglyceridem ia w as -2 .4
fold greater than that seen in the young and older ZDF rats. This could relate to
the additional genetic potential of developing cardiovascular abnorm alities.
Since this is the first study using the hybrid ZDF/SHHF rat model, it is difficult to
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speculate on a contribution by genetic defects.

Pioglitazone, given to these

hybrid diabetic rats, dramatically improved, but did not totally normalize, plasma
triglyceride levels compared to untreated hybrid ZDF rats. There was no effect
seen in control rats from this drug. Vanadyl caused a significant decrease in
plasm a triglycerides, but only after 8 weeks of treatm ent and at the highest
concentration, which coincides with a significant decrease in plasma glucose.

D ecreased plasm a triglyceride levels are probably due to an increase in
clearance into tissues.

This has been reported in both norm al and obese

insulin resistant rats (Sugiyam a et al, 1990).

The increased clearance of

triglycerides can be explained by induction of the enzyme lipoprotein lipase that
removes triglycerides from the blood stream. Insulin resistance may decrease
triglyceride uptake by decreasing insulin's ability to induce lipoprotein lipase
(Ikeda et al., 1990).

A nother potentially im portant reason fo r decreased

triglyceride levels is that of enhanced insulin ability to inhibit adipose tissue
triglyceride lipase.

Free fatty acid levels were significantly elevated in the young and older ZDF
diabetic rat groups, but not in the young hybrid diabetic rats, compared to their
non-diabetic litterm ates.

Drug treatm ent did not significantly affect these

elevated lipid levels. T tiis suggests that correction of hypertriglyceridem ia is not
linked to enhanced insulin inhibition of triglyceride lipase since free fatty acids
and glycerol are the m ajor catabolic byproducts of triglyceride m etabolism .
Interestingly, the young ZDF rats, had much lower plasma free fatty acid levels
com pared to the older ZDF and young hybrid rats. The increased free fatty acid
levels in the older ZDF rats could be due to their hypoinsulinem ic state. Insulin
is known to stimulate lipoprotein lipase and facilitate removal of free fatty acids
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from the blood stream into tissues.

In the presence of little insulin, free fatty

acids rise, potentially explaining why free fatty acid levels were higher in the
older than in the younger rats.

Lipoprotein profiles in ZDF rats were also affected by diabetic state.

Young,

older and hybrid ZDF diabetic rats showed elevated total cholesterol levels
com pared to non-diabetic litterm ates.

Pioglitazone treatm ent significantly

reduced, but did not normalize, plasma total cholesterol levels in the young ZDF
dia b e tic group w hile it norm alized total cholesterol in the young hybrid
ZDF/SHHF diabetic rats. Pioglitazone did not change total cholesterol levels in
the older ZD F diabetic rats. This failure to lower total cholesterol is probably
due to the conversion from NIDDM to IDDM during the study. HDL cholesterol
levels were elevated in young and hybrid ZDF diabetic rats compared to non
diabetic litterm ates.

HDL levels in older ZDF diabetic rats appeared to be

elevated, how ever a 45% standard error preclude significance.

Although

pioglitazone decreased plasm a triglycerides in the young and hybrid diabetic
rats, it did not decrease HDL levels implying that the triglycerides are derived
from LDL and VLDL lipoproteins. There was no significant effect of pioglitazone
in the young, old o r hybrid non-diabetic rats with respect to total or HDL
cholesterol.

In KKAV mice, pioglitazone caused a 58% reduction in LDL and

VLDL and a 25% increase in HDL cholesterol (Castle et al., 1993). It has been
suggested that reduction in cholesterol levels m ay be due to a reduction in
triglyceride levels that could produce an increase in lipoprotein lipase activity
secondary to augmented insulin action (Sugiyam a et al., 1990).

Hydralazine

had no significant effect on plasm a lipoprotein profiles in older ZD F diabetic
rats, but did sign ifican tly low er total ch ole stero l levels in young hybrid
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ZD F/SH H F diabetic rats and significantly elevated HDL cholesterol levels in
young hybid ZDF/SHHF diabetic rats.

Hem oglobin A1C (HbA1c) levels are a measure of glycosylated hemoglobin as
a result of consistently elevated plasma glucose levels. It is indicative of relative
plasm a glucose control over the prolonged periods of 3 weeks or more. HbA1c
was not measured in young ZDF rats, but was in the older and hybrid rats. In
the older and hybrid rats a small, but significant, increase in HbA1c levels was
observed in diabetic untreated rats compared to non-diabetic untreated rats.
None of the drug treatm ents (pioglitazone, vanadyl or hydralazine) affected
these levels in the older ZDF diabetic rats. Pioglitazone significantly decreased
HbA1c levels in young hybrid ZDF/SHHF diabetic rats to levels seen in non
diabetic untreated rats.

This indicates that pioglitazone provided excellent

glucose control in young NIDDM (hybrid) diabetic rats. Vanadyl had no effect
on H b A lc levels in e ith e r o ld e r o r hybrid rats, possibly because the
concentration of the drug was only at optimal levels for a week and would not
significantly affect H b A lc levels during that short period of time.

Sustained obesity is associated with cardiac hypertrophy and com prom ised
ventricular function. In order to assess cardiovascular performance and overall
ca rd iova scula r health, we m easured left ve n tricu la r developed pressure,
m aximum rate of force developm ent (+dP/dt) and maximum rate of relaxation
(-dP/dt) In the isolated perfused working heart apparatus using glucose as the
sole source of energy. W e also determined ventricular levels of cholesterol and
triglycerides and observed heart weights and heart weight to body weight ratios.
In a dd ition , systolic, d ia sto lic and m ean a rte ria l blood p re ssu re s w ere
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determ ined in conscious restrained rats using a semi-automated tail cuff device.
As an added component, vascular reactivity was investigated in aortic strips.

O besity results in increased metabolic demands, one of which is for oxygen. To
com pensate for this, cardiac output increases, more specifically either stroke
volum e increases induced due to increased filling pressures (preload) (Paulson
and Tahillani, 1992) or heart rate increases to increase cardiac output.

This

increased preload, over a period of time, results in left ventricular hypertrophy.
In som e cases, both preload and afterloads increase resulting in cardiomegaly.
T his is opposite to hypertension induced hypertrophy w hich results from
increased arterial blood pressure (afterload). In obese patients, autopsy results
indicate increased heart weights, prim arily due to increased left ventricular
mass, an increase which correlates well with increased body weight.

As a heart tries to compensate for increased filling pressures and thus becomes
larger, there exists the possibility for ischemic episodes, myocardial infarction or
heart failure. STZ-diabetic rats consistently show elevated heart weight to body
weight ratios (McNeill, 1985); however, in STZ-diabetic animals, body weight is
low er than in non-diabetic controls.

To date there is no published data

concerning heart weights in ZDF rats or hybrid ZDF/SHHF rats when exposed to
oral hypoglycemic agents.

In our study, none o f the d iabetic untreated rats (young, old o r hybrid)
posse ssed
litterm ates.

altered h e a rt w e ig h ts co m p are d to

untre ate d

n o n -d ia b e tic

Pioglitazone, how ever, caused a significant increase in heart

w eights in young ZDF and young hybrid ZDF/SHHF rats with no effect on the
older ZDF rats (IDDM). Vanadyl and hydralazine had no effect on heart weights
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in e ith e r diabetic or non-diabetic rats of young, old or hybrid ZDF origin.
H ypertrophy can be beneficial initially, but if the condition progresses, it can
lead to ve n tricu la r w all distention and w eakening w ith the potential for
decreased cardiac output and heart failure.

P io g lita zo n e did sign ifican tly increase heart w eights and body w eights;
however, the degree of increase was not proportional, resulting in a significantly
low ered heart w eight to body w eight ratio in the DP group com pared to
untreated young ZDF diabetic rats. There was no effect on heart weights or
body weights caused by pioglitazone In the young non-diabetic rats or in either
diabetic or non-diabetic older ZDF rats. Young hybrid ZDF/SHHF diabetic rats
treated with pioglitazone also had decreased heart weight to body weight ratios
which however, were not significant. Interestingly, hydralazine caused the non
diabetic group to have significantly elevated heart weight to body weight ratios
com pared to untreated control rats.

Normal hearts weigh approxim ately 4

percent of the body weight. If the heart weight decreases compared to the body
weight, the heart must work harder to properly perfuse the body. This can lead
to ischemia and other cardiovascular abnormalities.

The differences seen in heart w eight are interesting since the young ZDF
diabetic rats evidenced significantly impaired cardiac perform ance as reflected
by LVDP, +dP/dt and -dP/dt. In this group of rats, LVDP, +dP/dt and -dP/dt had
reduced function at the low est preload pressures tested.

Since no blood

pressure determ inations w ere m ade in the young ZDF rats, no association
between hypertension, hypertrophy and im paired overall cardiac perform ance
at low preloads can be made.

All that can be noted is that obesity can also

cause these same effects and the DP rats were obese.

This may be related to

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

88

ische m ia in the tissues, since at low perfusion pressures, the heart is
hypoperfused and may result in ischemia (personal communications, V. Yuen
and S. Dai, UBC). Potentially, these DP rats may be more prone to ischemic
episodes. To test this hypothesis, ischemia reperfusion studies would have to
be conducted.

T his phenom enon was not present in the young hybrid ZDF/SHHF diabetic
p io g lita zo n e treated rats w hich also exhibited increased heart w eights.
Pioglitazone caused a significant enhancement in LVDP of hybrid rats relative
to diabetic untreated rats.

None of the rat groups exhibited a significant

im p a irm e n t of ca rd io va scu la r perform ance w hich is a w ell docum ented
phenom enon in animal models of IDDM. There may in fact be no good model
for cardiovascular impairment in NIDDM rats. There appeared to be a trend for
im paired function in the young ZD F diabetic rats, but this trend w as not
observed in the older ZDF model or the hybrid model.

O lder ZDF rats were specifically chosen fo r the second study because we
hypothesized that cardiom yopathy may not occur until later in the rat's life at a
tim e when diabetes has significantly progressed. As it turned out, we probably
did not use old enough rats. To compound this issue, w e determined that the
NIDDM rats slowly convert to IDDM rats, thus masking any cardiomyopathy that
might have evolved during the phase of NIDDM. It has, however, recently been
reported that cardiom yopathy does not occur in Zucker fatty rats until several
m onths of age (Rosen et al., 1986). The greatest effect that occurred in this
group of rats w as due to hydralazine.

H ydralazine significantly im paired

diabetic -dP/dt and improved noh-diabetic -dP/dt.
pressure, but had no effect on cardiac size.

Hydralazine lowered blood

It im paired rates of relaxation in
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diabetic rats, but Improved rates of relaxation In non-diabetic rats. This can not
be related to hyperinsulinem ia since It did not exist In these older ZDF rats.
Possibly, hydralazine Interferes with electrolyte balance, ultim ately affecting
calcium levels and contractility In the heart.

Hybrid ZDF/SHHF rats not only are obese, Insulin resistant and hyperllpidemic,
but they also have the potential to develop hypertension and/or congestive
heart failure due to an abnormal gene expressed In the ZDF strain. It is known
that cardiovascular com plications can be potentiated by hypertension and/or
other congenital heart defects. The possibility exists, that since this new hybrid
strain can develop other cardiovascular abnormalities, It possibly could develop
the "diabetic cardiom yopathy" observed In STZ-dlabetIc rats (IDDM).

Since

Impaired cardiovascular perform ance was not observed In either the young or
older ZDF diabetic rats tested, this hybrid strain of rats was chosen to took for
potential cardiom yopathy. The only effect seen In the young hybrid ZDF/SHHF
diabetic rats was with hydralazine treatm ent, which significantly im proved
diabetic -dP/dt compared to non-diabetic rats.

Diabetic cardiom yopathy by definition is cardiom yopathy which occurs In the
absence of any significant coronary artery disease.

Rats typically do not

develop coronary artery disease and thus are a good m odel for diabetic
cardiomyopathy. Vanadyl, which corrects the diabetic cardiomyopathy In STZdiabetic rats (Heyliger et al., 1986), had no effect In the older ZDF or hybrid
ZD F/SH H F rats.

Since significantly im paired cardiac perform ance w as not

observed in the diabetic rats, little Improvement could probably be expected.
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C ard ia c tissue cholesterol levels, corrected for protein content w ere not
Increased in young or older ZDF diabetic rat hearts compared to non-diabetic
ra t

h e a rts ,

but

w e re

s ig n ific a n tly

e le v a te d

in

th e

yo u n g

h y b rid

ZD F/SH H Fdiabetic rats. This increase in cardiac cholesterol in young hybrid
ZD F/SH H F diabetic rats is consistent with elevated plasma cholesterol levels
seen in this group. Pioglitazone had no effect on young, older or hybrid ZDF rat
heart cholesterol content despite an overall increase in heart w eight and a
decrease in plasma cholesterol in diabetic groups.

Hydralazine also had no

effect on cardiac cholesterol in young or older ZDF diabetic and non-diabetic rat
hearts, but did significantly decrease cardiac cholesterol in non-diabetic rats
relative to both diabetic and non-diabetic untreated rats.

Elevated cardiac triglycerides have been documented in the IDDM rat model,
the BB rat. Elevated plasma lipid concentrations can accumulate intracellularly
w here lipids m ight contribute to cardiac stiffness and interfere with various
enzyme systems. Cardiac tissue triglyceride levels were elevated in young and
older ZDF diabetic rats compared to non-diabetic littermates. Diabetic and non
diabetic cardiac triglyceride levels in the young ZDF rats were significantly
decreased by pioglitazone treatment. This could be due to a secondary effect of
pioglitazone to decrease circulating plasm a triglyceride levels.

It could,

however, be a direct effect of the drug to stim ulate lipoprotein lipase in the
cardiac tissue. Vanadyl normalized elevated cardiac triglyceride levels in the
older diabetic rats, but had no effect in non-diabetic rats. Pioglitazone had no
effect on this cardiac param eter in older ZDF diabetic rats. Once again this is
p robably due to the IDDM state.

A lthough hydralazine reduced plasm a

triglycerides significantly after 7 weeks of treatm ent, it significantly increased the
cardiac triglyceride levels of older ZDF diabetic rats.

Perhaps this is because
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plasm a triglycerides are being removed and subsequently deposited in tissues
such as the heart.

A nother possibility is that there is abnorm al fatty acid

m etabolism , such as reduced amounts of carnitine involved in m itochondrial
uptake of free fatty acids.

Levels of cardiac triglycerides in the young hybrid

ZD F/SH H F diabetic rats are not significantly different from the levels in non
diabetic rats.

Pioglitazone, hydralazine and vanadyl had no effect in either

d ia b e tic or n on -diabetic rats of hybrid origin.

The am ount of cardiac

triglycerides is lower in the young hybrid rats compared to the older ZDF rats
and the higher levels in older rats m ay be reflective of their IDDM where
elevated triglyceride levels have been previously noted.

Decreasing cardiac lipids is important for diabetics. In contrast to non-diabetics,
diabetic individuals tend to use more free fatty acids than glucose to function
norm ally.

If triglyceride levels are high, free fatty acid levels increase as

triglyceride lipase breaks down triglycerides.

Another potential problem with

elevated cardiac lipids is coronary artery disease or hypertension, two important
problem s associated with diabetic populations.

This suggests that any drug

capable of decreasing both plasm a and cardiac tissue lipids would be an
added benefit to NIDDM patients. This is the case with pioglitazone in young
ZDF diabetic rats and hydralazine in older ZDF diabetic rats.

H ype rten sion

has

been

a sso cia te d

w ith

h y p e rin su lin e m ia

and

insu lin

resistance in human subjects with essential hypertension and in various animal
m odels of hypertension including sp on ta ne ou sly hypertensive (SH) rats.
Several recent studies investigating the relationship between hyperinsulinem ia
and hypertension have indicated that hyperinsulinem ia may contribute to the
developm ent of hypertension in SH rats.

In separate studies, vanadyl sulfate
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a nd

b is (m a lto la to )o x o v a n a d iu m (lV )

(an

o rg a n ic

v a n a d iu m

c o m p le x )

concom itantly decreased plasma insulin and blood pressure (Bhanot, S., et al,
Hypertension, in press; Bhanot, S., et al, 1994). Vanadyl sulfate has also been
shown to prevent fructose-induced hyperinsulinem ia and hypertension in rats
(Bhanot, S., et al., 1993).

CS-045, another thiazolidinedione, has also been observed to have concurrent
insulin and blood pressure lowering effects in 7 month old obese Zucker rats
(Yoshioka et al., 1993). Since these rats were not hyperglycemic, it rules out
the possibility that hyperglycem ia caused the hypertension.

In a study using

pioglitazone in Insulin resistant rhesus monkeys, the drug decreased insulin,
glucose, triglycerides and blood pressure, indicating an association between
insulin resistance and hypertension in these anim als (Kemnitz, J.W ., et al.,
1994).

It has recently been suggested that the hypotensive a ctivity of

pioglitazone is not alw ays associated with normal insulin sensitivity (Zhang,
H.Y., et al., 1994). These authors suggest that pioglitazone's ability to decrease
peripheral resistance in Dhal salt rats (insulin resistant) may be due to inhibited
growth of vascular smooth muscle cells as a result of alterations in intracellular
calcium.

A study, investigating the relationship between intracellular calcium

and hypertension in obese rats, determ ined that decreased insulin and blood
pressure correlated with a significantly decreased capacity of platelet-derived
growth factor BB hom odim er to induce sustained increases in intracellular free
calcium (Pershadsingh, H.A., et al, 1993).

This study suggests that a novel

pharm acological approach to the treatm ent of hypertension m ight be to modify
cell calcium responses to pressor agents, growth factors, or both.
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Systolic, diastolic and mean arterial blood pressures were not determined in the
young ZD F rats.

O lder ZDF diabetic rats did not exhibit any hypertension

com pared to non-diabetic rats.

The absolute value of systolic and diastolic

blood pressures in both diabetic and non-diabetic rats is m ildly elevated
com pared to what has been reported for non-obese rats.
s tu d ie s

in Z u c k e r rats w hich

This agrees with

ind icate th a t s ig n ific a n t c a rd io v a s c u la r

abnorm alities do not occur until several months of age.

Although we named

these ZDF rats older, they are only 5 months old at the end of the experiment.

In th e young hybrid ZD F/SH H F rats, hydralazine significantly decreased
systolic, diastolic and mean arterial blood pressures in both diabetic and non
diabetic rat groups compared with untreated littermates. Hydralazine is known
to be a direct arterial vasodilator; moreover, hydralazine caused a concomitant
decrease in plasm a triglyceride levels in the diabetic rats.

This triglyceride

lowering effect was also seen by Rodrigues et al., (1986) in STZ-diabetic rats
and o ccurre d co n cu rre n tly w ith decreased systolic blood pressure and
improved cardiac perform ance.

Our results do not indicate improved cardiac

perform ance in the diabetic rats, but do suggest improved cardiac performance
in non-diabetic rats.

H ydralazine increased the rate of relaxation w ithout

changing the rate of force development or left ventricular developed pressure.
Young hybrid ZD F/SH H F diabetic rats had sim ilar systolic and mean arterial
blood pressures to the older ZDF rats, but had lower diastolic blood pressures.
As in the older ZD F rats, there w as no difference in blood pressure between
diabetic and non-diabetic rats.

In this study, hydralazine tended to cause a

decrease in blood pressure (-9 % decrease in systolic; -1 0 % decrease in
d iastolic; -1 2 % decrease in m ean arterial blood pressure in diabetic rats)
w hich, how ever, did not attain significance.

In this study, p io g lita zo ne
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sign ifican tly reduced the systolic (10%), diastolic (11%) and mean arterial
(12%) blood pressures of diabetic rats compared to control untreated rats. This
effect occurred concom itantly with decreased plasma glucose, triglycerides,
cholesterol and insulin. Several of these parameters could have contributed to
th e

h y p o te n s iv e

e ffe c ts

of

p io g lita z o n e .

H ow e ver,

c o rre c tin g

th e

hyperinsulinem ia present in these rats may play a significant role since no effect
was seen in our older, insulin deficient, ZDF rats (IDDM).

Some m em bers of the research community have expressed concern about the
reliability of non-invasive, tail cuff blood pressure determinations.
several reasons to believe the validity of our readings.

There are

First, the rats were

acclim ated to the surroundings on several occasions to establish baseline
responses before th e ir determ inations.

Second, the rats were housed in

tem perature controlled conditions. Third, there are several papers which have
determ ined that there is no significant difference between invasive and noninvasive blood pressure readings (Bhanot, S., et al., 1994).

Fourth, we

observed an expected decrease in blood pressure upon treatm ent with a direct
vasodilator, hydralazine.

Vascular reactivity is a m easure of the sensitivity of vascular tissue, such as
aortas, to certain pharm acological agents, such as norepinephrine.

Many

studies have been conducted to evaluate vascular sensitivity and reactivity.
Results of these studies show increased, decreased or no change in vascular
reactivity, depending on the experim ental conditions and animal model used.
To date, there is very little evidence that there is any change in NIDDM rats. It is
believed that increased sensitivity may be associated with hypertension.
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O ld e r ZD F diabetic rats had significantly h igher m axim um responses to
norepinephrine than did non-diabetic littermates. As this group of rats closely
resembles IDDM, this is consistent with previously published results (Gattu, M.,
1993). Pioglitazone decreased aortic sensitivity in the older ZDF diabetic rats,
but had no effect on non-diabetic littermates. The effects of pioglitazone in this
instance are probably not a direct effect of the drug since these rats were
hypoinsulinem ic and insulin is necessary for pioglitazone to exert its effects. In
these rats, there was no effect of the drug on blood pressure, so this Improved
vascular characteristic can not be entirely responsible for changes in blood
pressure. Likewise, vanadyl sulfate improved vascular sensitivity in older ZDF
diabetic rats with no effect on non-diabetic rats and no corresponding effects on
blood pressure. Hydralazine, on the other hand, had no effect on diabetic rats,
but significantly increased sensitivity in non-diabetic rats. Hydralazine also had
a concom itant blood pressure lowering effect in both diabetic and non-diabetic
rats.

This does not agree with the theory that increased vascular sensitivity

results in hypertension.

Maximum vasoconstriction to the depolarizing agent,

KCl (40 mM), in these older ZDF diabetic rats was also significantly greater than
non-diabetic litterm ates.

This is opposite to the decreased effect in IDDM

reported by Gattu (1993) and Fulton (1991). Possibly this is because these rats
had not been insulin dependent for a significant period of time as they belatedly
converted from NIDDM to IDDM.

P ioglitazone and vanadyl decreased

va so re a ctivity in d ia b e tic rats w hile h ydrala zine increased n on -d iab e tic
responsiveness.

In the young hybrid ZDF/SHHF diabetic rats, a significant difference was not
observed in vascular sensitivity compared with non-diabetic rats. Pioglitazone,
vanadyl and hydralazine also had no effect on vascular sensitivity in this model
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of NIDDM. This agrees with previous results in young ZDF diabetic rats (Gattu,
M., 1993).

Since there was a significant blood pressure lowering effect seen

with pioglitazone treatm ent in these hyperinsuliném ie rats, but no effect on
vascular sensitivity, hypertension could be produced from some means other
than vascular impairment.

It is probably more likely that hyperinsulinem ia or

insulin resistance is responsible for, and certainly associated with, hypertension
in young hybrid ZDF/SHHF rats. Maximum response to 40 mM KCl was also
not affected by either disease or drug therapy. This is in agreement with the
results of Gattu (1993), who observed similar results in young ZDF diabetic rats.
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C O N C L U S IO N S

P ioglitazone reduced hyperglycem ia, hyperlipidem ia and hyperinsulinem ia
e ffe ctive ly at a dose an oral dose of 10 m g/kg/d ay when adm inistered
c h ro n ic a lly

to

yo u n g

ZDF

and

yo un g

h y b rid

Z D F /S H H F

d ia b e tic

hyperinsulinémie rats. The reduction of plasma glucose in hyperinsulinémie but
not hypoinsulinem ic NIDDM rats indicates that pioglitazone's m echanism of
action involves reversal of insulin resistance.

The reduction of plasm a

cholesterol levels by pioglitazone appears to be associated with decreased
LDL since HDL levels were not affected, and plasm a triglyceridses were
dram atically reduced.

Pioglitazone promotes a potentially detrimental gain in

body w eight in ZDF and hybrid ZDF/SHHF NIDDM rats.

It was evident that

pioglitazone impaired maximum left ventricular pressure and rates of force
developm ent and relaxation in young ZDF diabetic rats relative to non-diabetic
untreated rats at the lowest filling pressures and improved m axim um left
ventricular developed pressure in non-diabetic rats relative to untreated non
diabetic rats. Pioglitazone caused increased heart weights and body weights in
both young and hybrid ZDF diabetic rats and potentially decreased heart weight
to body w eight ratios (seen in young ZDF diabetic rats, but not hybrid
ZD F/SH H F diabetic rats).

Pioglitazone, however, significantly lowered blood

pressure in the young diabetic hybrid ZDF/SHHF rats relative to th eir non
diabetic litterm ates at a tim e when the untreated diabetic anim als had blood
pressures that approxim ated those of control littermates.

Since pioglitazone

lowered blood pressure in diabetic hybrid ZDF/SHHF rats, but not in their
control littermates, the implication is that pioglitazone lowers blood pressure by
its a b ility to co rre ct h ype rin suline m ia by re-establishing norm al insulin
sensitivity.
97
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Vanadyl sulfate (0.75 mg/ml), adm inistered orally In drinking water, improved
hyperglycem ia in older ZDF diabetic rats as a concom itant body w eight loss
o ccu rre d .

It im proved but did not norm alize the h ype rg lycem ia and

hypertriglyceridem ia of hybrid ZDF/SHHF diabetic rats without changing body
weights. This suggests that vanadyl's mechanism of action Is distinctly different
from the mechanism of pioglitazone to reduce plasma glucose and lipids.

Hydralazine (5 mg/kg b.i.d.), administered orally, effectively decreased plasma
cholesterol in hybrid ZDF/SHHF diabetic rats and plasma triglycerides in older
ZDF diabetic rats. Hydralazine improved the rates of relaxation in non-diabetic
o ld e r Z D F rats by im proving rates of relaxation, in contrast, hydralazine
im paired rates of relaxation in older ZDF diabetic rats at the higher preloads.
However, in the hybrid ZDF/SHHF rats indicated that diabetic rats treated with
hydralazine im proved relative to non-diabetic rats with respect to rates of
relaxation.
N ID D M

There w ere no changes in cardiac cholesterol levels in the two

rat gro up s (young ZD F and hybrid ZD F/S H H F) w hile cardiac

triglycerides decreased in young hybrid ZDF/SHHF diabetic rats treated with
hydralazine com pared to non-diabetic rats.

Hydralazine significantly reduced

blood pressure in the older ZDF rats and tended to lower blood pressures in the
young hybrid ZD F/SH H F rats.

The m echanism of action of hydralazine to

reduce blood pressure is through direct vasodilation, w hich is obviously
distinctly different from the mechanism by which of pioglitazone reduces blood
pressure.

E valuation of the ca rd io va scu la r param eters m easured in th ese studies
indicated that neither young, old or hybrid ZDF diabetic rats are a good model to
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stu dy diabetic ca rd iova scula r abnorm alities that m anifest them selves as
im paired cardiac perform ance or increased vascular reactivity.

Since no

im paired ca rd io va scu la r im pairm ent occurred w ith respect to these two
param eters in diabetic rats, it is prem ature to speculate on the potential
beneficial or detrimental effects of pioglitazone, vanadyl or hydralazine. Thus,
the NIDDM rat models used in the present study were not useful for determining
cardiovascular abnorm alities associated with diabetes in the isolated perfused
working heart apparatus during the time frame tested.

In addition to the aforementioned results, systolic, diastolic and mean arterial
blood pressures were not elevated in the insulin resistant NIDDM diabetic rats
relative to non-diabetic litterm ates in the hybrid ZDF/SHHF model.

Data

suggest that the blood pressures in this genetic rat model are higher than
normal regardless of diabetic status.

Thus, none of these NIDDM rat models

appear to be good m odels in which to study hypertension related to insulin
resistance in NIDDM, and it can be speculated that hyperinsulinemia especially
if short term is not predictive of an ensuing elevation of blood pressure.
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